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INTRODUCTION
The colloidal drug carriers have the potential to afford site specific as well
as targeted drug delivery. The idea of using submicron drug delivery systems for
drug targeting was conceived and developed after Paul Ehrlich originally proposed
the idea of tiny drug-loaded magic bullets over a hundred year ago. Among these
carriers,  liposomes  and  micro/nanoparticles  have  been  the  most  extensively
investigated.  Liposomes  present  some  technological  limitations  including  poor
reproducibility  and  stability,  and  low drug entrapment  efficiency.  Nevertheless,
several low molecular weight drugs are now commercially available which employ
this technology. 
Nanotechnology
The word “Nano” is derived from Greek word Dwarf , means “a billionth ” .A
Nanometer  is  billionth  of  a  meter,  which  is  250  millionth  of  an  inch  ,  about
1/80,000 of the diameter of a human hair or 10 times of the diameter of hydrogen
atom. The term ‘Nanotechnology’ was coined by Prof. Norio Taniguchi, Tokyo
Science University in 1974 to describe the precision manufacture of materials with
nanometers tolerances and was unknowingly appropriated by Drexler in his 1986
book ‘Engines of creation: The Coming Era of Nanotechnology. 
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Nanoparticles
Nanoparticles are sub-nano sized colloidal structure of synthetic or semi synthetic
polymer  .The  first  reported  nanoparticles  were  based  on  non  biodegradable
polymeric  system (polyacrylamide,  polymethyl-methaacrylate,  polystyrene).  The
polymeric  nanoparticles  can  carry  drug(s)  or  proteineous  substances,  i.e.
antigen(s). These bio-active agents are entrapped in polymer matrix as particulates
or  solid  solution  or  may  bound  to  particle  surface  by  physical  adsorption  or
chemically. The drug(s) may be added during preparation of nanoparticle or to the
previously prepared nanoparticles.  The structure of nanoparticles was shown in
Figure. 1.
Figure: 1, Structure of nanoparticle
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The  term  particulates  are  suggestively  general  and  doesn’t  account  for
morphological  and  structural  organization  of  system.  Nanomedicine  is  an
emerging field of medicine with novel applications. 
Nanomedicine is a subset  of  nanotechnology,  which uses tiny particles that are
more than 10 million times smaller than the human body. In nanomedicine, these
particles  are  much  smaller  than the  living  cell.  Because  of  this,  nanomedicine
presents many revolutionary opportunities in the fight against all types of cancer,
neurodegenerative disorders and other diseases.1
Polymeric nanoparticles
Polymeric  nanoparticles,  which  possess  a  better  reproducibility  and  stability
profiles  than  liposomes,  have  been  proposed  as  alternative  drug  carriers  that
overcome many of these problems. Nanoparticles are solid colloidal particles with
diameters ranging from 1-1000 nm. They consist of macromolecular materials and
can be used therapeutically as adjuvant in vaccines or drug carriers, in which the
active  ingredient  is  dissolved,  entrapped,  encapsulated,  adsorbed  or  chemically
attached. Polymers used to form nanoparticles can be both synthetic and natural
polymers. 
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 The polymeric nanoparticles are prepared from biocompatible and biodegradable
polymers  in  size  between 10-1000 nm where  the  drug  is  dissolved,  entrapped,
encapsulated or attached to a nanoparticle matrix. Depending upon the method of
preparation  nanoparticles,  nanospheres  or  nanocapsules  can  be  obtained.
Nanocapsules are systems in which the drug is confined to a cavity surrounded by
a unique polymer membrane, while nanospheres are matrix systems in which the
drug is physically and uniformly dispersed. The field of polymer nanoparticles is
quickly expanding  and playing  an important  role  in  a  wide  spectrum of  areas
ranging  from  electronics,  photonics,  conducting  materials,  sensors,  medicine,
biotechnology, pollution control and environmental technology. 
Polymeric  nanoparticles  are  promising  vehicles  for  drug  delivery  by  easy
manipulation  to  prepare  carriers  with  the  objective  of  delivering  the  drugs  to
specific  target;  such  an  advantage  improves  the  drug  safety.  Polymer-based
nanoparticles effectively carry drugs, proteins, and DNA to target cells and organs.
Their nanometer-size promotes effective permeation through cell membranes and
stability  in  the  blood  stream.  Polymers  are  very  convenient  materials  for  the
manufacture of countless and varied molecular designs that can be integrated into
unique nanoparticle constructs with many potential medical applications. Several
methods have been developed during the last two decades for preparation of PNPs,
these techniques are classified according to whether the particle formation involves
a polymerization reaction or nanoparticles form directly from a macromolecule or
preformed polymer or ionic gelation method.2,3
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 Advantages of polymeric nanoparticles 
• Increases  the  stability  of  any volatile  pharmaceutical  agents,  easily  and
cheaply fabricated in large quantities by a multitude of methods. 
• They offer a significant improvement over traditional oral and intravenous
methods of administration in terms of efficiency and effectiveness. 
• Delivers  a  higher  concentration  of  pharmaceutical  agent  to  a  desired
location.  The choice of polymer and the ability to modify drug release from
polymeric  nanoparticles  have  made  them  ideal  candidates  for  cancer
therapy,  delivery  of  vaccines,  contraceptives  and  delivery  of  targeted
antibiotics. 
• Polymeric  nanoparticles  can  be  easily  incorporated  into  other  activities
related to drug delivery, such as tissue engineering. 
Mechanisms of drug release 
The polymeric drug carriers deliver the drug at the tissue site by any one of
the three general physico-chemical mechanisms. 
• By the  swelling  of  the  polymer  nanoparticles  by hydration  followed by
release through diffusion. 
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• By an enzymatic reaction resulting in rupture or cleavage or degradation of
the  polymer  at  site  of  delivery,  there  by  releasing  the  drug  from  the
entrapped inner core. 
• Dissociation  of  the  drug  from the  polymer  and  its  de-adsorption/release
from the swelled nanoparticles.4,5
Polymers used in preparation of nanoparticles 
The polymers should be compatible  with the  body in the terms of  adaptability
(non-toxicity)  and  (non-antigenicity)  and  should  be  biodegradable  and
biocompatible. 
Natural polymers
• Chitosan 
• Gelatin 
• Sodium alginate 
• Albumin 
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Synthetic polymers 
• Polylactides(PLA) 
• Polyglycolides(PGA) 
• Poly(lactide co-glycolides) (PLGA) 
• Polyanhydrides 
• Polyorthoesters 
• Polycyanoacrylates 
• Polycaprolactone 
• Poly glutamic acid 
• Poly malic acid 
• Poly(N-vinyl pyrrolidone) 
• Poly(methyl methacrylate) 
• Poly(vinyl alcohol) 
• Poly(acrylic acid) 
• Poly acrylamide 
• Poly(ethylene glycol) 
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• Poly(methacrylic acid)[2] 
There are two types of nanoparticles depending on the preparation process:
nanospheres  and  nanocapsules.  Nanospheres  have  a  monolithic-type  structure
(matrix)  in  which  drugs  are  dispersed  or  adsorbed  onto  their  surfaces.
Nanocapsules exhibit a membrane-wall structure and drugs are entrapped in the
core or adsorbed onto their exterior. The term “nanoparticles” is adopted because it
is often very difficult to unambiguously establish whether these particles are of a
matrix or a membrane type.6,7,8  
Nanoparticles not only have potential as drug delivery carriers as they offer
non-invasive routes of administration such as oral, nasal and ocular routes, but also
show to be good adjuvant for vaccines. Despite these advantages, there is no ideal
nanoparticle  system  available.  Most  of  nanoparticles  prepared  from  water-
insoluble polymers are involved heat, organic solvent or high shear force that can
be harmful to the drug stability. 
Moreover, some preparation methods such as emulsion polymerization and
solvent evaporation are complex and require a number of preparation steps that are
more time and energy consuming. In contrast, water-soluble polymers offer mild
and simple preparation methods without the use of organic solvent and high shear
force.
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Criteria  for  ideal  polymeric  carriers  for  nanoparticles  &  nanoparticle
delivery systems
• Polymeric carriers
• Easy to synthesize and characterize
• Inexpensive
• Biocompatible
• Biodegradable
• Non-immunogenic
• Non-toxic
• Water soluble
Nanoparticle delivery systems
• Simple and inexpensive to manufacture and scale-up
• No heat, high shear forces or organic solvents involved in their preparation
process
• Reproducible and stable
• Applicable  to  a  broad  category of  drugs;  small  molecules,  proteins  and
polynucleotides
• Ability to lyophilize
• Stable after administration
• Non-toxic9,10
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LITERATURE  REVIEW
Among  water-soluble  polymers  available,  chitosan  is  one  of  the  most
extensively studied. This is because chitosan possesses some ideal properties of
polymeric  carriers  for  nanoparticles  such  as  biocompatible,  biodegradable,
nontoxic, and inexpensive. Furthermore, it possesses positively charge and exhibits
absorption  enhancing  effect.  These  properties  render  chitosan  a  very attractive
material as a drug delivery carrier. In the last two decades, chitosan nanoparticles
have been extensively developed and explored for pharmaceutical applications. 11
Properties of chitosan making it suitable for oral delivery 
• Biocompatibility and biodegradability 
• Permeation enhancing effect 
• Mucoadhesiveness 
• pH sensitiveness 
• Mild gelation conditions 
CHITOSAN NANOPARTICLE 
Chitosan based Nanoparticles have advantages particularly for the design
and  engineering  of  novel  Nanoparticulate  drug  delivery  systems,  due  to  their
desirable properties such as: 
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• Biocompatibility, 
• Biodegradability, 
• Bio– and mucoadhesivity, and 
• Hydrophilic character that facilitate the administration of poorly absorbable
drugs across various epithelial barriers, such as corneal, nasal and intestinal
mucosa. 
Chitosan Nanoparticles have been shown to provide sustained release of
both  hydrophilic  and  hydrophobic  drugs  and  are  prepared  by  three  distinct
methods  including  ionic  gelation,  precipitation  using  tripolyphosphate  and
crosslinking  methods  using  gluteraldehyde.  The  method  used  for  preparation
determines the entrapment efficiency, loading efficiency, and particlesize. Particle
size  of  the  Chitosan  Nanoparticles  generally  depends  on  molecular  weight  of
chitosan  used,  concentration  of  chitosan  solution  and  amount  of  cross  linker.
Increasing the concentration of chitosan increases the viscosity of chitosan solution
thus making smaller sized particle formation difficult.
An additional advantage of this type of system is that they can be produced
under  aqueous  and  fairly  mild  conditions,  thus  effectively,  being  especially
suitable to preserve the bioactive conformation of delicate macromolecules (e.g.
hormones, antigens, DNA, RNA, growth factors), that otherwise would be prone to
enzymatic degradation and hydrolysis. Most frequently Chitosan Nanoparticles are
formed according to a bottom–up approach as a  result  of  a  self–assembling or
crosslinking processes  in  which the  molecules  arrange themselves  into  ordered
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nanoscale  structures  either  by  physical  or  covalent  inter–  or  intramolecular
interactions. In these nanostructures, the drug can be entrapped or attached to the
Nanoparticles  matrix.  Chitosan  Nanoparticles  have  been  prepared  by  several
methodologies, including physical crosslinking by ionic gelation by specific ions
such as pentasodium tripolyphosphate (TPP) or EDTA. In particular, chitosan –
TPP Nanoparticles have been utilized as a drug delivery platform for a wide range
of active molecules. 12, 13
 
Chitosan
Chitosan is  a biopolymer that has received much attention and has been
extensively  studied  for  micro-  and  nonoparticles  preparation.  Properties  like
biodegradability, low toxicity and good biocompatibility make it suitable for use in
biomedical  and  pharmaceutical  formulations  as  antidiabetic  agents,  anti-
inflammatory  drugs,  immobilization  of  enzymes  and  protein,  ophthalmology.
Chitosan, a linear polyaminosaccharide is  obtained by alkaline deacetylation of
chitin, which is the second abundant polysaccharide next to cellulose. Chitin is the
main  component  of  protective  cuticles  of  crustaceans  such  as  crabs,  shrimps,
prawns, lobsters and cell walls of some fungi such as Aspergillus and mucor. The
structure of chitin and chitosan is shown in Figure. 2.
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Figure: 2, Structure of chitin and chitosan
Chitin is a homopolymer composed of β-(1,4)-linked Nacetyl- glucosamine
units  while  chitosan  comprises  copolymers  of  glucosamine  and  N-
acetylglucosamine.  Although  chitin  is  insoluble  in  most  solvents,  chitosan  is
soluble  in  most  organic  acidic  solutions  at  pH less  than  6.5  including  formic,
acetic,  tartaric,and  citric  acid.  It  is  insoluble  in  phosphoric  and  sulfuric  acid.
Chitosan  is  available  in  a  wide  range  of  molecular  weight  and  degree  of
deacetylation. Molecular weight and degree of deacetylation are the main factors
affecting the particle size, particles formation and aggregation.
 Chitosan has one primary amino and two free hydroxyl groups for each C6
building  unit.   Due  to  the  different  ways  of  applications,  chitosan  has  been
formulated as powder,  gels  and films,  sponges,  intragastric  floating tablets  and
especially spherical particles (micro- and nanoparticles). 14,15
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Specifications & characteristics of pharmaceuticalgrade chitosan
The pharmaceutical requirements for chitosan include: a white or yellow
appearance (powder or flake), particle size < 30 m, density between 1.35 and 1.40
g/cm3, a pH of 6.5 to 7.5, moisture content < 10%, residue on ignition <0.2%,
protein content <0.3%, degree of deacetylation 70% to 100%, viscosity <5 cps,
insoluble matter <1%, heavy metals (As) <10 ppm, heavy metals (Pb) <10 ppm,
and no taste and smell.
Different techniques used for the preparation of nanoparticles using natural
polymers 
Common  methods  to  prepare  chitosan  nanoparticles  are  ionic  gelation,
coacervation or precipitation, emulsion-droplet coalescence, reverse micellar, and
self-assembly chemical modification. The ionic gelation process is commonly used
to prepare chitosan nanoparticles because it is a very simple and mild method. This
process can be performed either by chemical or physical crosslinking. 
1. Emulsion Cross linking 
In this process, chitosan solution is emulsified in oil (w/o emulsion). The
aqueous droplets are stabilized using a suitable surfactant. The emulsion is then
reacted with an appropriate crosslinking agent such as glutaraldehyde, to stabilize
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the polysaccharide droplets. The Nanoparticles are then washed and dried. Ohya et
al reported for the first time the preparation of Chitosan Nanoparticles containing
5-fluorouracil  using  w/o  emulsion  method  followed  by  glutaraldehyde  cross
linking.  These  pioneering  studies  demonstrated  the  feasibility  of  preparing
Chitosan Nanoparticles that could bind and delivery drugs. Major drawbacks of
this method are associated with the use of organic solvents and cross linking agents
that may adversely affect the stability of proteins. Moreover, glutaraldehydes cross
linked Nanoparticles present negative effects on cell viability. 16,17,18
2. Spray-drying 
Spray-drying is a well-known technique to produce powders, granules or
agglomerates  from  the  mixture  of  drug  and  excipient  solutions  as  well  as
suspensions. The method is based on drying of atomized droplets in a stream of hot
air. In this method, chitosan is first dissolved in aqueous acetic acid solution, drug
is then dissolved or dispersed in the solution and then,  a suitable cross-linking
agent is added. This solution or dispersion is then atomized in a stream of hot air.
Atomization  leads  to  the  formation  of  small  droplets,  from  which  solvent
evaporates  instantaneously  leading  to  the  formation  of  free  flowing  particles.
Various process parameters are to be controlled to get the desired size of particles.
Particle  size  depends  upon  the  size  of  nozzle,  spray  flow  rate,  atomization
pressure, and inlet. Huang et al. prepared chitosan–iron oxide Nanoparticles with
various chitosan: iron oxide ratios by spray-drying. 19, 20
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3. Reverse Micellar Method 
In this method surfactant is first dissolved in an organic solvent to produce
reverse micelles. To this, an aqueous solution of chitosan and drug are added with
constant vortexing to avoid any turbidity. The aqueous solution is kept in such a
way as to keep the entire mixture in an optically transparent microemulsion phase.
Additional amount of water may be added to obtain Nanoparticles of larger size.
To  this  solution,  a  crosslinking  agent  is  added  and  the  mixture  kept  overnight
under  constant  stirring.  The  organic  solvent  is  then  evaporated  to  obtain  the
transparent dry mass. The material is dispersed in water, followed by the addition
of  a  suitable  salt,  which  helps  to  precipitates  the  surfactant  out.  It  is  then
centrifuged  and  the  supernatant  decanted,  which  contains  the  drug-loaded
Nanoparticles.  The aqueous dispersion is immediately dialysed through dialysis
membrane for about 1 hr. and the liquid is lyophilized to dry powder. 21
4. Template Polymerization 
In  this  technique,  chitosan  is  firstly  dissolved  in  an  acrylic  monomer
solution under magnetic stirring. Due to the electrostatic interaction, the negatively
charged  acrylic  monomers  align  along  the  chitosan  molecules.  After  complete
dissolution  of  chitosan,  the  polymerization  is  started  by  adding  the  initiator
(K2S2O8)  under  stirring  at  70ºC.  The  complete  polymerization  leads  to  the
appearance of an opalescent solution, indicating the Nanoparticles formation. The
Nanoparticles  solution  are  then  filtered  and  dialysed  to  remove  the  residual
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monomers  and initiator.  The obtained Nanoparticles  are positively charged and
present a size in the range of 50 to 400 nm. 22
5. Precipitation 
There are two kinds of approaches for Nanoparticle precipitation. One is
desolvation, in which flocculant (commonly sodium sulfate) is added to a water
solution of chitosan and solubility of chitosan is decreased by the combination of
water  and  sodium sulfate,  leading  to  the  precipitation  of  Nanoparticles  due  to
hydrogen bonding between molecules. This method was first applied by Berthold
et al to prepare chitosan microspheres. Technical improvements then enabled Tian
and Groves  prepare  600-  to  800-nm chitosan  Nanoparticles.  The  other  type  is
based on diffusion of emulsified solvent. Under the action of emulsified solvent,
the water phase containing chitosan is dispersed in the organic phase encapsulating
the drug, where turbulence appears between the interfaces of the two phases and
chitosan  is  precipitated,  resulting  in  the  generation  of  Nanoparticles.  In  this
method, organic solvent is used and the large Nanoparticles obtained restricting
their application. 23
6. Ionotropic gelation or Ionic gelation
Chitosan NP prepared by ionotropic gelation technique was first reported by
Calvo, and has been widely examined and developed. The mechanism of chitosan
NP formation is based on electrostatic interaction between amine group of chitosan
and negatively charge group of polyanion such as tripolyphosphate. This technique
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offers a simple and mild preparation method in the aqueous environment. First,
chitosan can be dissolved in acetic acid in the absence or presence of stabilizing
agent, such as poloxamer, which can be added in the chitosan solution before or
after the addition of polyanion. Polyanion or anionic polymers was then added and
nanoparticles  were  spontaneously  formed  under  mechanical  stirring  at  room
temperature. The size and surface charge of particles can be modified by varying
the ratio of chitosan and stabilizer. 24
7. Microemulsion method
Chitosan NP prepared by microemulsion technique was first developed by
Maitra. This technique is based on formation of chitosan NP in the aqueous core of
reverse micellar droplets and subsequently cross-linked through glutaraldehyde. In
this  method,  a  surfactant  was  dissolved  in  N-hexane.  Then,  chitoan  in  acetic
solution  and  glutaraldehyde  were  added  to  surfactant/hexane  mixture  under
continuous  stirring  at  room  temperature.  Nanoparticles  were  formed  in  the
presence of surfactant.  The system was stirred overnight to complete the cross-
linking  process,  which  the  free  amine  group  of  chitosan  conjugates  with
glutaraldehyde. 
The organic solvent is then removed by evaporation under low pressure.
The yields obtained were the cross-linked chitosan NP and excess surfactant. The
excess  surfactant  was  then  removed  by  precipitate  with  CaCl2  and  then  the
precipitant was removed by centrifugation. The final nanoparticles suspension was
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dialyzed before lyophilyzation. This technique offers a narrow size distribution of
less than 100 nm and the particle size can be controlled by varying the amount of
glutaraldehyde  that  alter  the  degree  of  cross-linking.  Nevertheless,  some
disadvantages exist such as the use of organic solvent, time-consuming preparation
process, and complexity in the washing step. 
8. Emulsification solvent diffusion method
El-Shabouri reported chitosan NP prepared by emulsion solvent diffusion
method, which originally developed by Niwa employing PLGA. This method is
based on the partial miscibility of an organic solvent with water. An o/w emulsion
is obtained upon injection an organic phase into  chitosan solution containing a
stabilizing  agent  (i.e.  poloxamer)  under  mechanical  stirring,  follow  by  high
pressure  homogenization.  The emulsion is  then diluted with  a  large amount  of
water  to  overcome  organic  solvent  miscibility  in  water.  Polymer  precipitation
occurs as a result  of  the diffusion of organic solvent into water,  leading to the
formation  of  nanoparticles.  This  method  is  suitable  for  hydrophobic  drug  and
showed high percentage of drug entrapment. The major drawbacks of this method
include harsh processing conditions (e.g., the use of organic solvents) and the high
shear forces used during nanoparticle preparation. 25, 26,27,28,29
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9. Polyelectrolyte complex (PEC)
Polyelectrolyte  complex  or  self  assemble  polyelectrolyte  is  a  term  to
describe complexes formed by self-assembly of the cationic charged polymer and
plasmid  DNA.  Mechanism  of  PEC  formation  involves  charge  neutralization
between  cationic  polymer  and  DNA leading  to  a  fall  in  hydrophilicity  as  the
polyelectrolyte component self assembly. Several cationic polymers (i.e. gelatin,
polyethylenimine)  also  possess  this  property.  Generally,  this  technique  offers
simple  and  mild  preparation  method  without  harsh  conditions  involved.  The
nanoparticles spontaneously formed after addition of DNA solution into chitosan
dissolved  in  acetic  acid  solution,  under  mechanical  stirring  at  or  under  room
temperature. The complexes size can be varied from 50 nm to 700 nm. 30
Among all the mentioned methods, ionic gelation technique is selected to
prepare the chitosan nanoparticles of valsartan. Here the ionic gelation process is
dicussed briefly. 
Ionic gelation
Ionic  gelation (IG),  earlier  known  as  'ion-induced  gelation',  results  in
nanoparticles and microparticles. The mucoadhesive properties of chitosan, due to
molecular attractive forces formed by electrostatic interaction between positively
charged chitosan and negatively charged mucosal  surfaces is  well  documented.
These properties may be attributed to
 (a) Strong hydrogen bonding groups like -OH, -COOH
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(b) Strong charges
 (c) High molecular weight
(d) Sufficient chain flexibility  
(e) Surface energy properties favoring spreading into the mucus
Cross linking agents
It is worth noting that chitosan has a high density of amine groups in its
backbone and the amine groups are protonized to form -NH3 + in acidic solution.
These positively charged groups in chitosan can be chemically cross-linked with
dialdehydes  such  as  glutaraldehyde  and  ethylene  glycol  diglycidyl  ether,  or
physically  cross-linked  with  multivalent  anions  derived  from  sodium
tripolyphosphate (TPP), citrate and sulphate. 
Advantages of tripolyphosphate  
Glutaraldehyde and ethylene glycol diglycidyl ether are toxic and can cause
irritation to mucosal membranes. Physically cross-linked chitosan gels have been
used  in  drug  delivery  systems  due  to  their  enhanced  biocompatibility  over
chemically cross-linked chitosan. Non-toxicity and quick gelling ability of TPP are
the important properties that make it a favourable cross-linker for ionic gelation of
21
chitosan. In addition, TPP has been also recognized as an acceptable food additive
by the US Food and Drug Administration. 
Moreover, the process of ionic gelation of chitosan with TPP as a cross-
linker is feasible for the scale-up of entrapment in a particle processing operation.
Chitosan  nanoparticles  prepared  by  TPP  as  an  anionic  cross-linker  are
homogeneous, and possess positive surface charges that make them suitable for
mucosal adhesion applications. The properties of ionically cross-linked chitosan
are influenced by electrostatic interactions between the anionic cross-linker and
chitosan. 31, 32
Nature of interaction
This  interaction  depends  on  the  variables  such  as:  anionic  molecular
structure, its charge density and molecular concentration, pH of chitosan solution,
and  physical  properties  of  chitosan,  i.e.,  molecular  weight  and  degree  of
deacetylation  (DDA).  Several  studies  have  investigated  the  effect  of  these
variables  on  the  properties  of  ionically produced  chitosan,  its  drug entrapment
efficiency and drug release behavior. 33
In  the  ionic  gelation  method,  the  positive  or  negative  charge  of  the
hydrophilic  polymer  is  complexed  with  a  multivalent  cationic  (e.g.  calcium
chloride) or polyanionic (e.g. sodium tripolyphosphate) to form highly viscous gel
particles  with  a  size  in  the  range  of  a  nanometer.  Ionic  gelation  method  was
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developed by Calvo and Coworkers for the preparation of chitosan nanoparticles.
In  this  method  polymer  solutions  and  polyanion  solutions  are  mixed  to  form
nanoparticles.
Counterions 
The counterions used for ionotropic gelation can be divided into two major
categories: 
(i) Low molecular weight counterions
                (e.g. CaCl2, BaCl2, MgCl2, CuCl2, ZnCl2, CoCl2, pyrophosphate,
tripolyphosphate, tetrapolyphosphate, octapolyphosphate, hexametaphosphate and
[Fe(CN)6]-4 / [Fe(CN)6]-3;
           (ii) High molecular weight ions 
                (e.g. octyl sulphate, lauryl sulphate, hexadecyl sulphate, cetylstearyl
sulphate). The ionotropic gelation method is very simple and mild. In addition,
reversible  physical  crosslinking  by electrostatic  interaction  instead  of  chemical
crosslinking avoids the possible toxicity of reagents and other undesirable effects.
34
Mechanism of cross linking
 The basic  mechanism involved in  the  formation of  nanoparticles  is  the
electrostatic  interactions  between  positively  charged  amino  groups  present  in
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polymer and negatively charged anion. The mechanism of cross linking was shown
in Figure. 3.
Figure: 3. Mechanism of cross linking
In  other  words  it  can be seen  that  in  the  ionic  gelation  method,  due  to
interaction the material undergoes transition from liquid to gel phase. The obtained
chitosan nanoparticles generally are of small size in the range of 200-500nm.
First, chitosan can be dissolved in acetic acid in the absence or presence of
stabilizing agent, such as poloxamer, which can be added in the chitosan solution
before or after the addition of polyanion. Polyanion or anionic polymers was then
added and nanoparticles were spontaneously formed under mechanical stirring at
room temperature. The size and surface charge of particles can be modified by
varying the ratio of chitosan and stabilizer.
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The basic concept is that a polycationic polymer in aqueous solution passes,
in  appropriate  conditions,  from  sol  to  dispersed  gel  following  electrostatic
crosslinking with an adequate anionic substance.  This technique has been used
with  several  quaternized  chitosans  carrying  fixed,  pH-independent  positive
charges, the most known of which is N-trimethyl chitosan (TMC). 
Sodium tripolyphosphate (TPP) has widely been employed as the ionotropic
crosslinker.  The  nanoparticles  prepared  by  ionotropic  gelation  of  quaternized
chitosans with TPP were generally 200-300 nm in size,  i.e.,  smaller than those
obtained  by the  same method  starting  from plain  chitosan  which,  by the  way,
showed lesser stability and tended to re-dissolve after some time from formation.
The zeta potential was always positive, in the 10-20 mV range. 
The solution of the chitosan derivative into which the TPP solution was
dripped would often contain a surfactant, usually Tween 80, to hinder nanoparticle
aggregation  and  facilitate  their  re-dispersion  after  centrifugation.  In  fact,
centrifugation was necessary to clear the particles of non-encapsulated drug. 35
 The thiolated nanoparticles formed by ionotropic gelation with TPP were
stabilized via oxidation of  thiols  with  H2O2 which formed interchain disulfide
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bonds.  These  would  bestow gastroresistance  on  the  particles,  which  would  be
particularly  appropriate  in  case  of  oral  administration  of  the  nanoparticle
formulation.  However  the  presence  of  some  non-oxidized  thiols  on  the
nanoparticle  surface was needed to  confer enhanced mucoadhesivity on such a
surface.
Applications of chitosan nanoparticles
Carrier for various drugs
1. Carrier of gene drugs
As  a  gene  carrier,  conventional  virus  has  the  disadvantages  of  low
transfection rate and cell toxicity, and even causes serious immune response. As a
nonvirus carrier, chitosan has excellent biocompatibility and biodegradation, which
has led to increasing application of chitosan nanoparticles in gene drug delivery.
Gene silencing mediated by double-stranded small interfering RNA (siRNA) has
been widely investigated as a potential therapeutic approach for diseases caused by
genetic  defects.  However,  its  application is  restricted by rapid  degradation and
poor  cell  absorption.  Drug  loading of  chitosan nanoparticles  prepared by ionic
gelation by Katas and Alpar reached 100%, protecting well siRNA from nuclease
degradation. 
With  natural  positive  ion  chitosan  as  a  carrier  material  and  using
electrostatic interaction of polyelectrolyte, siRNA of silencing green fluorescent
protein was compounded directly by Liu55 to prepare stable siRNA nanoparticles
with a complex rate of 83% to 94%. 
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2. Carrier of protein drugs
Protein drugs can be degraded easily by enzymes in vivo and have poor
permeability  and  stability  as  well  as  a  short  half-life.  However,  chitosan  can
protect  protein  well  and  promote  the  contact  between  drug  and  biomembrane,
thereby improving bioavailability. Gan and Wang showed that changing the size
and surface charge of chitosan–bovine serum albumin nanoparticles could regulate
the encapsulation efficiency and release kinetics of bovine serum albumin, but it
was difficult to control the burst release of protein of high molecular weight. 
Zhang  used  insulin  and  cationic  β-cyclodextrin  to  form  a  complex
encapsulated into alginate–chitosan nanoparticles. Binding rate and drug-loading
amount  were 87% and 9.5%, respectively,  and cumulative release of insulin  in
simulated  intestinal  fluid  reached  40%.  Insulin  was  protected  well  in  the
nanoparticles core, avoiding the degradation in simulated gastric fluid, as well as
the structure of insulin during release. Glycol chitosan nanoparticles modified by
5β-cholanic  acid  (HGC)  and  RGD  (Arg-Gly-Asp)  polypeptide  were  easily
encapsulated into nanoparticles with a drug-loading amount greater than 85%.
3. Carrier of anticancer chemical drugs
Chitosan itself has a certain antitumor activity and its positive charge can
neutralize  the  negative  charge  on the  tumor  cell  surface,  resulting  in  selective
absorption.  Thus,  chitosan nanoparticles can increase  drug concentration in  the
tumor  site  and  improve  therapeutic  effects.  Doxorubicin/methoxy PEG grafted
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carboxymethyl chitosan nanoparticles with higher cell toxicity could enter cell and
inhibit tumor-cell proliferation effectively. Paclitaxel chitosan nanoparticles had a
high encapsulation rate of 94.0% ± 16.73% with sustained-release effect. Cell
toxicity testing showed that paclitaxel–chitosan nanoparticles had a higher toxicity
than that of paclitaxel alone, and with a higher cell uptake rate. 
4. Carrier of other drugs
Chitosan nanoparticles also can load other drugs including antivirus drugs,
antiallergic drugs, and hormone drug. Hao and Deng  prepared acyclovir-loaded
chitosan nanoparticles with a drug loading of 17.8% and an encapsulation rate of
87.5% by an ionic cross-linking method. Li and Luan prepared tranilast-loaded
chitosan nanoparticles for allergic diseases with a particle size of 285.5 nm and an
encapsulation rate of 82.4%. 36
5. Parenteral administration
Nano-sized  particles  can  be  administered  intravenously  because  the
diameter  of  the  smallest  blood  capillary  is  approximately  4  µm.  The  bio-
distribution of nanoparticles can vary depending on the size, surface charge and
hydrophobicity  of  the  administered  particles.  Particles  greater  than  100  nm in
diameter are rapidly taken up by the reticuloendothelial system (RES) in the liver,
spleen,  lung  and  bone  marrow,  while  smaller-sized  particles  tend  to  have  a
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prolonged circulation time. Negatively-charged particles are eliminated faster than
positively-charged or neutral particles. 
 The most promising drugs that have been extensively studied for delivery
by  this  route  are  anticancer  agents.  Following  intravenous  injection,  many
nanoparticle  systems  including  chitosan  NP  exhibited  a  marked  tendency  to
accumulate in a number of tumors. One possible reason for the phenomenon may
involve  the  leakiness  of  tumor  vasculature.  Doxorubicin  loaded  chitosan  NP
showed regression in tumor growth and enhance survival rate of tumor-implanted
rats after IV administration.
 In addition, chitosan NP less 100 nm in size have been developed which
showed to be RES evading and circulate in the blood for considerable amount of
time.  Delivery  of  antiinfectives  such  as  antibacterial,  antiviral,  antifungal  and
antiparasitic drugs is another common use of nanoparticles. The low therapeutic
index of antifungal drugs,  short half-life of  antivirals and the limited ability of
antibiotics  to  penetrate  infected  cells  in  intracellular  compartments  make  them
ideal candidates for nanoparticle delivery.  
Peroral administration
The  idea  that  nanoparticles  might  protect  labile  drugs  from  enzymatic
degradation  in  the  gastrointestinal  tract  (GIT)  leads  to  the  development  of
nanoparticles  as  oral  delivery  systems  for  macromolecules,  proteins  and  poly-
nucleotides.  This  approach  was  extensively  studied  after  a  report  that  blood
glucose levels were reduced in diabetic rats following the oral administration of
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insulin nanoparticles. Limiting nano-sized particles to less than 500 nm in diameter
seems to be a key factor in permitting their transport through the intestinal mucosa
most probably through an endocytotic mechanism. 
However,  besides  the  enzymes,  mucus  layer,  which hamper  diffusion of
drug molecules and nanoparticles, and the epithelial absorption barriers are main
hurdles  against  gastrointestinal  protein  drug  absorption.  Therefore,  drug
bioavailability  can  be  improved  by  controlling  the  particle  size  along  with
prolonging the residence time of drug carrier systems in GIT. Among polymeric
nanoparticles, chitosan NP showed to be attractive carriers for oral delivery vehicle
as they promote absorption of drug. 
The absorption promoting effect of chitosan has been extensively studied by
several research groups and found to be due to a combination of mucoadhesion
and transient opening of tight junctions in the mucosal cell membrane which have
been verified both  in vitro  and  in vivo. The mucoadhesive properties of chitosan
are  due  to  an  interaction  between  positively  charged  chitosan  and  negatively
charge of mucin which provide a prolonged contact time between the drug and the
absorptive surface, and thereby promoting the absorption. 
Chitosan muco-adhesion  is  also  supported by the  evidence that  chitosan
increases significantly the half time of its clearance. Furthermore, in vitro studies
in Caco-2 cells have shown that chitosan is able to induce a transient opening of
tight junctions thus increasing membrane permeability particularly to polar drugs,
including peptides and proteins. Recent studies have shown that only protonated
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soluble chitosan, in its uncoiled configuration, can trigger the opening of the tight
junctions, thereby, facilitating the paracellular transport of hydrophilic compounds.
 This property implies that  chitosan would be effective as an absorption
enhancer only in a limited area of the intestinal lumen where the pH values are
below  or  close  to  its  pKa.  Although  chitosan  was  able  to  open  up  the  tight
junctions, the uptake of particle > 50 nm could not be explained by a widening of
the intercellular spaces. Mechanism of chitosan NP transport across GIT is most
probably  through  adsorptive  endocytosis.  Electrostatic  interaction  between
positively charged chitosan and negatively charged sialic  acid of  mucin causes
association of chitosan NP to the mucus layer and subsequently internalization via
endocytosis. 
Recently,  chitosan was  demonstrated to  promote  the  nasal  absorption of
insulin in rats and sheep. However, the insulin-chitosan powder, chitosan blended
with insulin using pestle and mortar, showed to have bioavailability greater than
chitosan NP containing insulin.
Non-viral gene delivery vectors
Although viruses can efficiently transfer genes into cells, concerns such as
host  immune  response,  residual  pathogenicity,  and  potential  induction  of
neoplastic growth following insertional mutagenesis have led to the exploration of
non-viral  gene  transfer  systems.  These  latter  delivery  systems  are  generally
considered  to  be  safer  since  they  are  typically  less  immunogenic  and  lack
mutational potential. There are usually considered to be five primary barriers that
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must  be  overcome  for  successful  gene  delivery:  in  vivo  stability,  cell  entry,
endosome escape,  intracellular  trafficking and nuclear  entry.  Cationic  polymers
and  lipids  have  both  shown  promise  as  gene  delivery  agents  since  their
polycationic nature produces particles that reduce one or more of these barriers.
For example, by collapsing DNA into particles of reduced negative or increased
positive  charge,  binding  to  the  cell  surface  and  enhanced  endocytosis  may be
promoted. 
In many cases, cationic polymers seem to produce more stable complexes
thus  offering  more  protection  during  cellular  trafficking  than  cationic  lipids.
Among  cationic  polymers,  PEI  is  particularly  promising  as  a  vector  given  its
relatively  high  level  of  transfection  in  a  number  of  target  organs  by  various
delivery routes. The high charge density of PEI is thought to be a key factor that
contributes  to  its  high  transfection  efficiency.  Unfortunately,  the  polycationic
nature of PEI also appears to be the main origin of its marked toxicity, a property it
shares with many other polycations (e.g. polylysine). 
This toxicity has severely limited its use as a gene delivery vector in vivo.
On the contrary,  chitosan is  a cationic  polymer  with  extremely low toxicity.  It
showed significantly lower toxicity than poly-L-lysine and PEI.  Additionally,  it
enhances the transport of drug across cell membrane as discussed earlier. Chitosan
as  a  promising  gene  delivery vector  was  first  proposed  by Mumper.  Chitosan
mediates efficient  in vitro  gene transfer at nitrogen to phosphate (N/P) ratio of 3
and 5. At these ratios, small chitosan-DNA complexes can be prepared in the range
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of 50-100 nm with a positively surface charge of approximately +30 mV. Sato et
al.  found that  in  vitro  chitosan-mediated transfection depends on the cell  type,
serum concentration, pH and molecular weight of chitosan.
Delivery of vaccines
Nanoparticles often exhibit significant adjuvant effects in parenteral vaccine
delivery since they may be readily taken up by antigent presenting cells. Moreover,
oral and nasal delivery of nanoparticles are thought to have the potential to provide
mucosal protective immune responses, one of the most desired goals of modern
vaccinology. The submicron size of nanoparticles allows them to be taken up by
M-cells, in mucosa associated lymphoid tissue (MALT) i.e. gut-associated, nasal-
associated and bronchus-associated lymphoid tissue,  initiating  sites  of  vigorous
immunological responses. Immunoglobulin A (IgA), a major immunoglobulin at
mucosal surface, and the generation of B-cell expressing IgA occur primarily in
MALT. The B-cell then leaves the MALT and reaches systemic circulation where
they clonally expand and mature into IgA plasma cells. Therefore, providing not
only protective  IgA at  the  pathogen  entered  sites,  but  also  systemic immunity.
There are two main administration routes for mucosal vaccine delivery, oral and
nasal.  The  main  targeted  for  oral  delivery  vaccine  are  Peyer’s  patches.  By
incorporating vaccine into nanoparticles systems, the vaccine is protected against
enzymatic degradation on its way to the mucosal tissue and efficiently taken up by
M-cells. 
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In contrast to oral administration, nasal administered vaccines have to be
transported over a very small distance, remain only about 15 minutes in the nasal
cavity,  and are  not exposed to low pH values  and degradative  enzymes.  Thus,
nasally  delivery  vaccines  may  not  necessary  formulated  as  nanoparticles  as
discussed earlier. It may be administered as solution or powder with absorption
enhancing agent to slow down mucociliary clearance process and thereby prolong
the contact time between the formulation and nasal tissue. Among the polymers
used to form vaccine nanoparticles, chitosan is one of the most recently explored
and extensively studied as prospective vaccine carriers. Its absorption promoting
effect is believed to improve mucosal immune response. 
The mechanism of action of chitosan in improving transport of drug across
mucosal  membrane  can  be  explained  by the  same theory as  discuss  earlier  in
peroral  administration  section.  Illum  et  al.  successfully  developed  chitosan
vaccines containing influenza, pertussis and diphtheria antigens for nasal delivery.
They demonstrated that  these vaccines produced a significant  antibody level  in
mice,  both  serum and  secretory IgA.  Despite  the  potential  carrier  for  mucosal
delivery vaccine, chitosan has also been reported to act as an adjuvant for systemic
vaccine  delivery  such  as  increasing  the  accumulation  and  activation  of
macropharges  and  polymorphonuclear  cells.  Activation  of  macropharges  is
initiated  after  uptake  of  chitosan.  Furthermore,  chitosan  has  also  been  widely
explored as the application for DNA mucosal vaccines. 37, 38 
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Ocular administration
Nanoparticles have been found to be potential carriers for ocular delivery
following the observation that various types of nanoparticles tend to adhere to the
ocular epithelial surface. The resulting prolonged residence time of nanoparticles
leads to a much slower elimination rate compared to conventional ophthalmologic
formulations,  thereby  improving  drug  bioavailability.  As  a  consequence,
nanoparticles  have  been  developed  for  targeted  ophthalmic  delivery  of  anti-
inflammatory, antiallergic and beta-blocker drugs. 
Among  mucoadhesive  polymers  explored  now,  chitosan  has  attracted  a
great  deal  of  attention  as  an  ophthalmic  drug  delivery  carrier  because  of  its
absorption  promoting  effect.  Chitosan  not  only  enhance  cornea  contact  time
through  its  mucoadhesion  mediated  by  electrostatic  interaction  between  its
positively charged and mucin negatively charged, its ability to transient opening
tight  junction is  believed to improve drug bioavailability.  Felt  et  al.  found that
chitosan solutions prolonged the cornea resident time of antibiotic in rabbits. 
Chitosan also shown to be  a low toxic material,  ophthalmic formulation
based on chitosan exhibited an excellent tolerance after applied chitosan onto the
rabbit’s corneal surface. Besides employing chitosan NP to improve drug transport
via ocular, chitosan-coated nanoparticles can also be utilized as it exhibited ability
to enhance the corneal penetration. In addition, De Campos et al. found that after
ocular administration of chitosan NP in rabbits, most of drugs were found in extra-
ocular  tissue,  cornea  and  conjunctiva,  while  negligible  drug  were  found  in
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intraocular  tissues,  iris/ciliary body and aqueous humor.  Together,  these  results
suggested  that  chitosan  NP  showed  to  be  attractive  material  for  ocular  drug
delivery vehicle with potential application at extra-ocular level. 
Valsartan  delivery  systems  based  on  chitosan-TPP  nanoparticles  are
reported in research works performed previously. A shortcoming of chitosan-based
nanoparticles as drug release system is that such particles release 30-70% of the
drug within 3-6 h placed in release environment. This is due to the mechanism of
burst release that has been considered as a slow release in many studies. 39
Burst release management is a major challenge in the development of drug
delivery systems because it may lead to inefficient delivery and significant toxicity
hazards.  The degree  of  burst  release  generally depends upon the  nature  of  the
polymer, drug molecular structure and its molecular weight, polymer/ drug ratio,
relative affinities of the drug and polymer and the aqueous phase. 
Polymer coating is another burst release control method. Tavakol et al have
studied this method for  N,O-carboxymethyl chitosan (NOCC) beads coated with
chitosan.  They produced beads of NOCC and alginate  with  ionotropic gelation
method and then, coated the beads with chitosan. The effect of coating and drying
methods on the swelling and release behaviour of the prepared beads has been
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investigated.  The  results  of  this  work  indicate  that  burst  release  has  not  been
observed in chitosan coated beads. Using additional barrier layers is naturally an
efficient method to manipulate drug release profiles and reduce the burst release,
though  it  is  inherently  an  expensive  method  due  to  the  additional  materials
employed and difficulties associated with controlling the barriers quality. 
In a study, Sarmento and co-workers prepared insulin-loaded alginate– CS-
NPs by ionotropic pre-gelation of dilute alginate solution with calcium chloride
followed PEC formation with CS. Particle size, association efficiency of insulin
into alginate NPs and loading capacity were influenced by various process and
formulation variables such as time and speed of stirring, alginate guluronic acid
content,  CS  molecular  weight  and  initial  alginate/CS  mass  ratio.  Upon
optimisation, high association efficiency (92%) and loading capacities (14.3%) of
insulin  were  achieved,  and  the  NPs  displayed  controlled  release  in  gastric  pH
(50%) for up to 24 h while extensive insulin release was noticed in intestinal pH
(75%) 
Chitosan, a cationic polysaccharide, is one of such biodegradable polymers,
which has been extensively exploited for the preparation of nanoparticles for oral
controlled delivery of several therapeutic agents. In recent years, the area of focus
has shifted from chitosan to chitosan derivatized polymers for the preparation of
oral  nanoparticles  due  to  its  vastly  improved  properties,  such  as  better  drug
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retention capability, improved permeation, enhanced mucoadhesion and sustained
release of therapeutic agents. 
The main objective of this work done by Morteza et al., was to reduce the
burst release of BSA-loaded chitosan nanoparticles prepared by a one-step simple
method. Very few studies have focused on high loadings (10-15%) of proteins in
micro/nanospheres with low burst release. Due to the nature of BSA, an optimum
BSA delivery system must undergo burst release as low as possible while keeping
drug loading as high as possible. The design of an optimum system is the main
objective of the study. 
 Intrinsic  characteristics  of  chitosan  enhance  the  transport  of  bioactives
across the cell membrane. For example, calcium, a poor absorbable nutrient, can
be entrapped into chitosan in order to improve the bioavailability.  Chitosan has
many  advantages  with  respect  to  nanoparticles  preparation  since  it  not  only
contains a number of free amine groups available for cross linking, but also for
controlling the release of bioactives. 40
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AIM AND PLAN OF WORK
Chitosan, a cationic polysaccharide, is one of such biodegradable polymers,
which has been extensively exploited for the preparation of nanoparticles for oral
controlled delivery of several therapeutic agents. In recent years, the area of focus
has shifted from chitosan to chitosan derivatized polymers for the preparation of
oral  nanoparticles  due  to  its  vastly  improved  properties,  such  as  better  drug
retention capability, improved permeation, enhanced mucoadhesion and sustained
release of therapeutic agents. 13
Valsartan  delivery  systems  based  on  chitosan-TPP  nanoparticles  are
reported in research works performed previously. A shortcoming of chitosan-based
nanoparticles as drug release system is that such particles release 30-70% of the
drug within 3-6 h placed in release environment. This is due to the mechanism of
burst release that has been considered as a slow release in many studies. 9
Burst release management is a major challenge in the development of drug
delivery systems because it may lead to inefficient delivery and significant toxicity
hazards.  The degree  of  burst  release  generally depends upon the  nature  of  the
polymer, drug molecular structure and its molecular weight, polymer/ drug ratio,
relative affinities of the drug and polymer and the aqueous phase. 10
Polymer coating is another burst release control method. Tavakol et al have
studied this method for  N,O-carboxymethyl chitosan (NOCC) beads coated with
chitosan.  They produced beads of NOCC and alginate  with  ionotropic gelation
method and then, coated the beads with chitosan. The effect of coating and drying
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methods on the swelling and release behaviour of the prepared beads has been
investigated.  The  results  of  this  work  indicate  that  burst  release  has  not  been
observed in chitosan coated beads. 11
In a study, Sarmento and co-workers prepared insulin-loaded alginate– CS-
NPs by ionotropic pre-gelation of dilute alginate solution with calcium chloride
followed PEC formation with CS. Particle size, association efficiency of insulin
into alginate NPs and loading capacity were influenced by various process and
formulation variables such as time and speed of stirring, alginate guluronic acid
content,  CS  molecular  weight  and  initial  alginate/CS  mass  ratio.  The  NPs
displayed controlled release in gastric pH (50%) for up to 24 h while extensive
insulin release was noticed in intestinal pH (75%) 12
Intrinsic  characteristics  of  chitosan  enhance  the  transport  of  bioactives
across the cell membrane. For example, calcium, a poor absorbable nutrient, can
be entrapped into chitosan in order to improve the bioavailability.  Chitosan has
many  advantages  with  respect  to  nanoparticles  preparation  since  it  not  only
contains a number of free amine groups available for cross linking, but also for
controlling the release of bioactives. 14
The main objective of the work done by Morteza et al., was to reduce the
burst release of BSA-loaded chitosan nanoparticles prepared by a one-step simple
method. 
Chitosan  nanoparticles  were  fabricated  by  ionotropic  gelation  technique
which gives many advantages including a simple, mild preparation method without
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the use of organic solvents and high shear force. Precise control of particle size is
central in chitosan nanoparticles preparation. The ionotropic gelation of chitosan
forms  the  inter  and  intramolecular  linkages  between  positively  charged  amine
group of chitosan and negatively charged polyanion such as tripolyphosphate.
Valsartan is a selective angiotensin II receptor antagonist used treatment of
hypertension.  It  is  poorly soluble in  water.  It  is  reported that  bioavailability of
valsartan  is  23-25%  after  oral  dose.  Peak  plasma  concentration  of  valsartan
achieves at 2-4 hours after a oral  dose.  Due to the reasons mentioned the drug
valsartan selected and an attempt was made to formulate chitosan nanoparticles in
two ways that is to formulate plain chitosan nanoparticles and alginate chitosan
nanoparticles with calcium chloride to compare the burst control and to improve
the bioavailability.25
The  formulated  chitosan  nanoparticles  will  be  an  alternate  for  the
formulations  with  chitosan  with  more  burst  release  and  can  improve  the
bioavailability of the drug valsartan with less burst release.
.
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PLAN OF WORK
1. Determination of max of valsartan
2. Calibration curve for the drug in phosphate buffer pH 6.8
3. Drug polymer interaction study by using FTIR
4. Formulation of chitosan nanoparticles of valsartan by ionic gelation technique
by using    different concentrations of chitosan alone and chitosan with sodium
alginate  and  calcium chloride  to  compare  the  burst  release  of  drug  in  both
systems.
5. Evaluation of particle size
6. Calculation of percentage yield.
7. Determination of percentage drug entrapment efficiency
8. Determination of zeta potential.
9. Measurement of mean particle size.
10. Evaluation of in vitro drug release.
11. Comparisons of In –vitro release pattern of optimized chitosan nanoparticles of
valsartan with marketed formulations.
12. Accelerated stability studies of optimized chitosan nanoparticles of valsartan.
MATERIALS AND EQUIPMENTS
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MATERIALS USED
1. Drug- Valsartan                           - Shasun laboratories
2. Chitosan                                                     - Shasun laboratories
3. Sodium alginate                                           - Shasun laboratories
4. Calcium chloride                                               - Shasun laboratories
5. Tripolyphosphate                                   - Shasun laboratories
6. Acetic acid                                                       - S.D.Fine chem Ltd
               
7. Di-sodium hydrogen phosphate   - Vin biotech systems             
                                                                                      
8. Calcium chloride                           - Nice chemicals
9. Sodium hydroxide   - Nice chemicals
EQUIPMENTS USED
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1. Mechanical stirrer                              - Bombay India ltd.
2. Malvern zeta sizer                             - SM, UK.     
3. Electronic Balance           - A&D Company, Japan.
4. Magnetic Stirrer           - MC Dalal & co. 
5. UV Visible Spectrophotometer        - UV Pharma spec 1700, Shimadzu.
6. FTIR Spectrophotometer                 - Perkin Elmer.
7. Environmental chamber                   - Inlab equipments (Madras pvt ltd).
8. Centrifuge                                        - Inlab equipments.
9. Freeze drier                                      -   Rocktech.
DRUG PROFILE
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Valsartan: 
Valsartan is  an angiotensin-receptor  blocker  (ARB) that  may be used  to
treat a variety of cardiac conditions including hypertension, diabetic nephropathy
and  heart  failure.  Valsartan  lowers  blood  pressure  by  antagonizing  the  renin-
angiotensin-aldosterone  system  (RAAS);  it  competes  with  angiotensin  II  for
binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood
pressure  increasing  effects  of  angiotensin  II.  Unlike  angiotensin-converting
enzyme (ACE)  inhibitors,  ARBs do  not  have the  adverse  effect  of  dry cough.
Valsartan may be used to treat  hypertension,  isolated systolic hypertension,  left
ventricular  hypertrophy  and  diabetic  nephropathy.  It  may  also  be  used  as  an
alternative agent for the treatment of heart failure, systolic dysfunction, myocardial
infarction and coronary artery disease. 41
Categories: 
Antihypertensive Agents, Angiotensin II Receptor Antagonists
Structural formula:
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Systematic name:
Valsartan is chemically described as N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-
yl) [1, 1'-biphenyl]-4-yl] methyl]-L-valine. 
Chemical Formula:     C24H29N5O3 
Average mass:              435.518799 Da
Monoisotopic mass:     435.227051 Da
Appearance:               white powder
Melting Point:              117 °C 
Solubility:   Slightly soluble in water, soluble in alcohol, Soluble to 100 mM in
DMSO 
        Stability: Stable. Incompatible with strong oxidizing agents
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Classes:  Biphenyltetrazoles and Derivatives 42, 43,44
Pharmacodynamics:
Valsartan belongs to a class of antihypertensive agents called angiotensin II
receptor blockers (ARBs). Valsartan is a specific and selective type-1 angiotensin
II  receptor (AT1) antagonist  which blocks the blood pressure increasing effects
angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a
homeostatic  mechanism  for  regulating  hemodynamics,  water  and  electrolyte
balance. During sympathetic stimulation or when renal  blood pressure or blood
flow  is  reduced,  renin  is  released  from  granular  cells  of  the  juxtaglomerular
apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin
I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. 
Angiotensin  II  increases  blood  pressure  by  increasing  total  peripheral
resistance,  increasing  sodium  and  water  reabsorption  in  the  kidneys  via
aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to
two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein
coupled  receptor  (GPCR)  that  mediates  the  vasoconstrictive  and  aldosterone-
secreting effects of angiotensin II. 
Studies  performed  in  recent  years  suggest  that  AT2  antagonizes  AT1-
mediated effects and directly affects long-term blood pressure control by inducing
vasorelaxation  and  increasing  urinary  sodium  excretion.  Angiotensin  receptor
blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the
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ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike
ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall
effect of ARBs is a decrease in blood pressure.
Mechanism of action:
Valsartan is an ARB that selectively inhibits the binding of angiotensin II to
AT1,  which is  found in  many tissues  such as vascular  smooth muscle  and the
adrenal  glands.  This  effectively inhibits  the  AT1-mediated  vasoconstrictive  and
aldosterone-secreting effects of angiotensin II and results in a decrease in vascular
resistance and blood pressure. Valsartan is selective for AT1 and has virtually no
affinity for AT2. Inhibition of aldosterone secretion may inhibit sodium and water
reabsorption in the  kidneys  while  decreasing potassium excretion.  The primary
metabolite  of  valsartan,  valeryl  4-hydroxy  valsartan,  has  no  pharmacological
activity.
Volume of distribution:
17 L (low tissue distribution)
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Protein binding:
94 - 97% bound to serum proteins, primarily serum albumin.
Half life: 
The initial phase t1/2 α is < 1 hour while the terminal phase t1/2 β is 5-9 hours.
Metabolism:
Valsartan is  excreted largely as unchanged drug (80%) and is  minimally
metabolized  in  humans.  The  primary circulating  metabolite,  4-OH-valsartan,  is
pharmacologically inactive and produced CYP2C9. 4-OH-valsartan accounts for
approximately  9%  of  the  circulating  dose  of  valsartan.  Although  valsartan  is
metabolized by CYP2C9, CYP- mediated drug-drug interactions between valsartan
and other drugs is unlikely. 45,46,47
Route of elimination:
83% of absorbed valsartan is excreted in feces and 13% is excreted in urine,
primarily as unchanged drug.
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Clearance:
2 L/h  [IV administration],  4.5  L/h  [heart  Failure  patients  receiving  oral
administration 40 to 160 mg twice a day]
Indication:
 May be  used as  a  first  line  agent  to  treat  uncomplicated  hypertension,
isolated systolic  hypertension and left  ventricular  hypertrophy.  Possibly will  be
used as a first line agent to delay progression of diabetic nephropathy. Losartan
may be also used as a second line agent in the treatment of congestive heart failure,
systolic dysfunction,  myocardial  infarction and coronary artery disease in those
intolerant of ACE inhibitors.
Side effects:
Valsartan  may  cause  side  effects  like  dizziness,  headache,  excessive
tiredness,  nausea,  diarrhea,  stomach  pain,  back  pain,  joint  pain,  blurry  vision,
cough, and rash.
Adult Hypertension: 
The recommended starting dose of Diovan (valsartan) is 80 mg or 160 mg
once daily when used as monotherapy in patients who are not volume-depleted.
Patients requiring greater  reductions  may be started at  the higher dose. Diovan
may be used over a dose range of 80 mg to 320 mg daily, administered once a day.
The antihypertensive effect is substantially present within 2 weeks and maximal
reduction is generally attained after 4 weeks. If additional antihypertensive effect
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is required over the starting dose range, the dose may be increased to a maximum
of 320 mg or a diuretic may be added. Addition of a diuretic has a greater effect
than dose increases beyond 80 mg. 
Storage:
The drug should be stored at 25°C (77°F).48,49
Applications in Pharmaceutical Formulations or Technology
Glacial  and  diluted  acetic  acid  solutions  are  widely  used  as  acidifying
agents in a variety of pharmaceutical formulations and food preparations. Acetic
acid is used in pharmaceutical products as a buffer system when combined with an
acetate  salt  such  as  sodium acetate.  Acetic  acid  is  also  claimed to  have  some
antibacterial and antifungal properties.
Description
Glacial acetic acid occurs as a crystalline mass or a clear, colorless volatile
solution with a pungent odor.
Pharmacopeial Specifications
Test                                               JP XV              PhEur 6.0               USP 32
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Identification Characters                  +                        +                           +
Freezing point                             ≥514.58C            ≥514.88C               ≥ 515.68C
Nonvolatile matter                     ≤ 41.0mg              ≤40.01%                 ≤41.0mg
Sulfate                                +                       +                             +    
Chloride                                           +                       +                             +
Heavy metals                             ≤410 ppm             ≤45 ppm                  ≤45 ppm
Iron                                                 —                    ≤ 45 ppm                       —
Readily oxidizable impurities           +                      +                              + 
Assay                                        ≥599.0%               99.5–100.5%        99.5–100.5%
Typical Properties
Acidity/alkalinity
pH = 2.4 (1M aqueous solution);
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pH = 2.9 (0.1M aqueous solution);
pH = 3.4 (0.01M aqueous solution).
Boiling point                   - 1188C
Dissociation constant     - pKa = 4.76
Flash point                      - 398C (closed cup); 578C (open cup).
Melting point                 - 17 
 C
Refractive index            -  n D20 = 1.3718
Solubility 
Miscible with ethanol, Ether, Glycerin, Water, and other fixed and volatile
oils
Specific gravity 
1.045
Stability and Storage Conditions
Acetic acid should be stored in an airtight container in a cool, dry place.
Incompatibilities
Acetic acid reacts with alkaline substances. 50,51,52
1. Calcium Chloride
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Structural Formula
Nonproprietary Names
Calcium Chloride Dihydrate
Calcium Chloride Hexahydrate
Synonyms
Calcii chloridum dihydricum; calcii chloridum hexahydricum.
Chemical Name and CAS Registry Number
Calcium chloride anhydrous [10043-52-4]
Calcium chloride dihydrate [10035-04-8]
Calcium chloride hexahydrate [7774-34-7]
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Empirical Formula and Molecular Weight
CaCl2 110.98 (for anhydrous)
CaCl2_2H2O 147.0 (for dihydrate)
CaCl2_6H2O 219.1 (for hexahydrate)
Functional Category
Antimicrobial preservative, therapeutic agent, water-absorbing agent.
Applications in Pharmaceutical Formulation or Technology
The  main  applications  of  calcium chloride  as  an  excipient  relate  to  its
dehydrating  properties  and,  therefore,  it  has  been  used  as  an  antimicrobial
preservative, as a desiccant, and as an astringent in eye lotions. Therapeutically,
calcium  chloride  injection  10%  (as  the  dehydrate  form)  is  used  to  treat
hypocalcemia.
Description
Calcium  chloride  occurs  as  a  white  or  colorless  crystalline  powder,
granules, or crystalline mass, and is hygroscopic (deliquescent).
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Typical Properties
Acidity/alkalinity - pH= 4.5–9.2 (5% w/v aqueous solution)
Boiling point - >1600  ̊  C (anhydrous)
Density (bulk) - 0.835 g/cm3 (dihydrate)
Melting  point -  772   ̊  C  (anhydrous),  176   ̊  C  (dihydrate),  30   ̊  C
(hexahydrate).
Solidification temperature 28.5–30  ̊  C (hexahydrate)
Solubility - Freely soluble in water and ethanol (95%), insoluble in diethyl
ether. 
Stability and Storage Conditions
Calcium chloride is chemically stable; however, it should be protected from
moisture. Store in air tight containers, in a cool and dry place.
Incompatibilities
Calcium  chloride  is  incompatible  with  soluble  carbonates,  phosphates,
sulfates, and tartrates. It reacts violently with bromine trifluoride, and a reaction
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with zinc releases explosive  hydrogen gas.   It  has an exothermic reaction with
water, and when heated to decomposition it emits toxic fumes of chlorine. 53,54,55
2. Sodium Alginate
Structural Formula
Nonproprietary Names
Sodium Alginate
Synonyms
Alginato sodico, algin, alginic acid, sodium salt, E401, Kelcosol, Keltone,
natrii alginas, Protanal, sodium polymannuronate.
Chemical Name and CAS Registry Number
Sodium alginate [9005-38-3]
Empirical Formula and Molecular Weight
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Sodium alginate consists chiefly of the sodium salt of alginic acid, which is
a mixture of polyuronic acids composed of residues of Dmannuronic acid and L-
guluronic  acid.  The  block  structure  and  molecular  weight  of  sodium  alginate
samples have been investigated.
Functional Category
Stabilizing agent, suspending agent, tablet and capsule disintegrant, tablet
binder, viscosity increasing agent.
Applications in Pharmaceutical Formulation or Technology
Sodium alginate  is  used  in  a  variety of  oral  and  topical  pharmaceutical
formulations. In tablet formulations, sodium alginate may be used as both a binder
and disintegrant; it has been used as a diluent in capsule formulations.
 Sodium alginate has also been used in the preparation of sustained-release
oral formulations since it can delay the dissolution of a drug from tablets, capsules,
and  aqueous  suspensions.  The  effects  of  particle  size,  viscosity  and  chemical
composition of  sodium alginate  on drug release  from matrix  tablets  have been
described.
In topical formulations, sodium alginate is widely used as a thickening and
suspending agent in a variety of pastes, creams, and gels, and as a stabilizing agent
for  oil-in-water  emulsions.  Recently,  sodium  alginate  has  been  used  for  the
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aqueous  microencapsulation  of  drugs,  in  contrast  with  the  more  conventional
microencapsulation techniques which use organicsolvent systems. 
It has also been used in the formation of nanoparticles. The adhesiveness of
hydrogels prepared from sodium alginate has been investigated, and drug release
from oral  mucosal  adhesive  tablets,  buccal  gels,  and  vaginal  tablets  based  on
sodium  alginate  have  been  reported.  The  esophageal  bioadhesion  of  sodium
alginate suspensions may provide a barrier against gastric reflux or site-specific
delivery of therapeutic agents. Other novel delivery systems containing sodium
alginate include ophthalmic solutions that form a gel in situ when administered to
the  eye;  an  in  situ  forming  gel  containing paracetamol  for  oral  administration;
nasal delivery systems based on mucoadhesive microspheres; and a freeze-dried
device  intended  for  the  delivery  of  bone-growth  factors.  Hydrogel  systems
containing  alginates  have  also  been  investigated  for  delivery  of  proteins  and
peptides.
 In  addition,  sodium  alginate  microspheres  have  been  used  in  the
preparation  of  a  footmouth  disease  DNA vaccine,  and  in  an  oral  vaccine  for
Helicobacter pylori;  chitosan nanoparticles coated with sodium alginate may have
applications in mucosal vaccine delivery systems.
Therapeutically, sodium alginate has been used in combination with an H2-
receptor  antagonist  in  the  management  of  gastroesophageal  reflux,  and  as  a
hemostatic agent in surgical dressings.
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Alginate dressings, used to treat exuding wounds, often contain significant
amounts  of  sodium  alginate  as  this  improves  the  gelling  properties.  Sponges
composed of sodium alginate and chitosan produce a sustained drug release and
may be useful as wound dressings or as tissue engineering matrices. Lyophilized
wound healing wafers composed of sodium alginate have been found to exhibit
large reductions in viscosity following gamma irradiation. Sodium alginate is also
used in cosmetics and food products; 
.
Description
Sodium  alginate  occurs  as  an  odorless  and  tasteless,  white  to  pale
yellowish-brown colored powder.
Typical Properties
Acidity/alkalinity pH - 7.2 (1% w/v aqueous solution)
Solubility -  Practically  insoluble  in  ethanol  (95%),  ether,  chloroform,  and
ethanol/water mixtures in which the ethanol content  is  greater  than 30%. Also,
practically  insoluble  in  other  organic  solvents  and  aqueous  acidic  solutions  in
which the pH is less than 3. 
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Slowly soluble  in  water,  forming  a  viscous  colloidal  solution.  Viscosity
(dynamic) various grades of sodium alginate are commercially available that yield
aqueous solutions of varying viscosity. Typically, a 1% w/v aqueous solution, at 20
 ̊  C,  will  have  a  viscosity  of  20–400  mPa  s  (20–400 cP).  Viscosity  may vary
depending upon concentration,  pH,  temperature,  or  the presence of  metal  ions.
Above pH 10, viscosity decreases 11.
Stability and Storage Conditions
Sodium alginate is a hygroscopic material, although it is stable if stored at
low  relative  humidities  and  a  cool  temperature.  Aqueous  solutions  of  sodium
alginate are most stable at pH 4–10. Below pH 3, alginic acid is precipitated. A 1%
w/v aqueous solution of sodium alginate exposed to differing temperatures had a
viscosity 60–80% of its original value after storage for 2 years. Solutions should
not be stored in metal  containers.  Sodium alginate solutions are susceptible on
storage to microbial spoilage, which may affect solution viscosity. Solutions are
ideally sterilized using ethylene oxide, although filtration using a 0.45 mm filter
also has only a slight adverse effect on solution viscosity. Heating sodium alginate
solutions to temperatures above 708C causes depolymerization with a subsequent
loss of viscosity. Autoclaving of solutions can cause a decrease in viscosity, which
may vary depending  upon the  nature  of  any other  substances  present.  Gamma
irradiation  should  not  be  used  to  sterilize  sodium alginate  solutions  since  this
process severely reduces solution viscosity. Preparations for external use may be
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preserved by the addition of 0.1% chlorocresol, 0.1% chloroxylenol, or parabens.
If the medium is acidic, benzoic acid may also be used. The bulk material should
be stored in an airtight container in a cool, dry place.
 Incompatibilities
Sodium alginate  is  incompatible with  acridine derivatives,  crystal  violet,
phenylmercuric  acetate  and nitrate,  calcium salts,  heavy metals,  and ethanol  in
concentrations  greater  than  5%.  Low  concentrations  of  electrolytes  cause  an
increase  in  viscosity  but  high  electrolyte  concentrations  cause  salting-out  of
sodium alginate; salting-out occurs if more than 4% of sodium chloride is present.
56,57
3. Chitosan 
 
Structural formula
Nonproprietary Names
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Chitosan Hydrochloride
Synonyms
2-Amino-2-deoxy-(1,4)-b-D-glucopyranan,  chitosani  hydrochloridum,
deacetylated  chitin,  deacetylchitin,  b-1,4-poly-D-glucosamine,  poly-D-
glucosamine, poly-(1,4-b-D-glucopyranosamine).
Chemical Name and CAS Registry Number
Poly-b-(1,4)-2-Amino-2-deoxy-D-glucose [9012-76-4]
Empirical Formula and Molecular Weight
Partial deacetylation of chitin results in the production of chitosan, which is
a  polysaccharide  comprising  copolymers  of  glucosamine  and  N-
acetylglucosamine. Chitosan is the term applied to deacetylated chitins in various
stages of deacetylation and depolymerization and it is therefore not easily defined
in terms of its exact chemical composition. A clear nomenclature with respect to
the different degrees of N-deacetylation between chitin and chitosan has not been
defined, and as such chitosan is not one chemical entity but varies in composition
depending  on  the  manufacturer.  In  essence,  chitosan  is  chitin  sufficiently
deacetylated to form soluble amine salts. The degree of deacetylation necessary to
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obtain a soluble product must be greater than 80–85%. Chitosan is commercially
available in several types and grades that vary in molecular weight by 10 000–1
000 000, and vary in degree of deacetylation and viscosity.
Functional Category
Coating  agent;  disintegrant;  film-forming  agent;  mucoadhesive;  tablet
binder; viscosity increasing agent.
Applications in Pharmaceutical Formulation or Technology
Chitosan is used in cosmetics and is under investigation for use in a number
of pharmaceutical formulations. The suitability and performance of chitosan as a
component of pharmaceutical formulations for drug delivery applications has been
investigated  in  numerous  studies.  These  include  controlled  drug  delivery
applications, use as a component of mucoadhesive dosage forms.
Description
Chitosan occurs as odorless, white or creamy-white powder or flakes. Fiber
formation  is  quite  common  during  precipitation  and  the  chitosan  may  look
‘cottonlike’.
Typical Properties
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Chitosan is a cationic polyamine with a high charge density at pH < 6.5, and
so adheres to negatively charged surfaces and chelates metal ions. It is a linear
polyelectrolyte with reactive hydroxyl and amino groups (available for chemical
reaction and salt formation). The properties of chitosan relate to its polyelectrolyte
and polymeric carbohydrate character. The presence of a number of amino groups
allows  chitosan  to  react  chemically  with  anionic  systems,  which  results  in
alteration of physicochemical characteristics of such combinations. The nitrogen in
chitosan  is  mostly  in  the  form  of  primary  aliphatic  amino  groups.  Chitosan
therefore  undergoes  reactions  typical  of  amines:  for  example,  N-acylation  and
Schiff reactions. Almost all functional properties of chitosan depend on the chain
length,  charge  density,  and  charge  distribution.  Numerous  studies  have
demonstrated that the salt form, molecular weight, and degree of deacetylation as
well as pH at which the chitosan is used all influence how this polymer is utilized
in pharmaceutical applications.
Acidity/alkalinity pH = 4.0–6.0 (1% w/v aqueous solution)
Density 1.35–1.40 g/cm3
Glass transition temperature 203  ̊  C
Moisture content 
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Chitosan  adsorbs  moisture  from  the  atmosphere,  the  amount  of  water
adsorbed  depending  upon  the  initial  moisture  content  and  the  temperature  and
relative humidity of the surrounding air.
Particle size distribution 
<30 mm
Solubility 
Sparingly soluble in water, practically insoluble in ethanol (95%), In other
organic solvents and neutral or alkali solutions at pH above approximately 6.5.
Chitosan dissolves readily in dilute and concentrated solutions of most organic
Stability and Storage Conditions 
Chitosan powder is  a  stable material  at  room temperature, although it  is
hygroscopic after drying. Chitosan should be stored in a tightly closed container in
a cool,  dry place.  The PhEur  6.5  specifies that  chitosan should be  stored at  a
temperature of 2–8  ̊  C.
 Incompatibilities 
Chitosan is incompatible with strong oxidizing agents. 58,59
4. Sodium triphosphate 
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Sodium triphosphate 
(STP, sometimes STPP or sodium tripolyphosphate or TPP) is an inorganic
compound with formula Na5P3O10. It is thesodium salt of the polyphosphate penta-
anion, which is the conjugate base of triphosphoric acid. It is produced on a large
scale  as  a  component  of  many  domestic  and  industrial  products,  especially
detergents.  Environmental problems associated with eutrophication are attributed
to its widespread use.
IUPAC name
Pentasodium triphosphate
Other names
Sodium tripolyphosphate, polygon, STPP
Molecular formula
Na5P3O10
Molar mass
367.864 g/mol
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Appearance
White powder
Density
2.52 g/cm3
Melting point
622 °C
Solubility in water
14.5 g/100 mL (25 °C)
Properties
STPP is a colourless salt, which exists both in anhydrous form and as the
hexahydrate.  The  anion  can  be  described  as  the  pentanionic  chain
[O3POP(O)2OPO3]. Many related di-, tri-, and polyphosphates are known including
the  cyclic  triphosphate  P3O93-.  It  binds  strongly  to  metal  cations  as  both
a bidentate and tridentate chelating agent.
Food applications
STPP is a preservative for seafood, meats, poultry,  and animal feeds. It  is
common  in  food  production  as E  number E451.  In  foods,  STPP  is  used  as
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an emulsifier and  to  retain  moisture.  Many governments  regulate  the  quantities
allowed in foods,  as it  can substantially increase the sale weight of  seafood in
particular.  The  United  States Food  and  Drug  Administration lists  STPP  as
"generally recognized as safe." 60,61
Other uses
Other uses (hundreds of thousands of tons/year) include "ceramics, leather
tanning (as masking agent  and synthetic tanning agent  -  SYNTAN), anticaking,
setting  retarders, flame
retardants,paper, anticorrosion pigments, textiles, rubber manufacture, fermentatio
n, antifreeze." TPP is used as a polyanion crosslinker in polysaccharide based drug
delivery.
EXPERIMENTAL METHODS
 CALIBRATION CURVE FOR VALSARTAN
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 PREPARATION OF CALIBRATION MEDIUM     
27.218 gm of potassium-di-hydrogen phosphate
 
was dissolved in sufficient
amount  of  distilled  water  to  make  1000ml  of  0.2M solution.  8  gm of  sodium
hydroxide  was  dissolved  in  sufficient  amount  of  distilled  water  to  make  one
1000ml  of  0.2M  solution.  From  the  above  solutions  50ml  of  potassium-di-
hydrogen  phosphate  solution  and  22.4ml  of  sodium  hydroxide  solutions  were
mixed and made up to 200ml with distilled water to get phosphate buffer solution
of pH 6.8. 
Preparation of standard curve for valsartan
 The  standard  stock  solution  of  valsartan  was  prepared  by dissolving  a
known amount of drug in phosphate buffer pH 6.8. From the above stock solution,
different concentrations of 10, 20......50λg /ml was prepared in same solution of
phosphate  buffer  pH  6.8.  The  resulting  solution  was  scanned  in  UV
Spectrophotometer  to  find  mmax  and  the  absorbance  was  measured  at  λmax
(250nm). The standard curve was plotted by taking concentration in X-axis and
absorbance in Y-axis. The standard curve was used to estimate drug content and
percentage drug release. 
FORMULATION  OF  VALSARTAN  CONTAINING  PLAIN  CHITOSAN
NANOPARTICLES AND ALGINATE CHITOSAN NANOPARTICLES BY
IONIC GELATION METHOD
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The  formulations  of  valsartan  containing  chitosan  nanoparticles  were
prepared  by  ionic  gelation  technique  and  there  were  nearly  six  formulations
formulated with different concentrations of chitosan and Tripolyphosphate. Among
the  six  formulations  three  were  prepared  with  chitosan  alone  and  three  were
prepared  with  sodium  alginate  and  calcium  chloride  to  get  optimum  size  of
nanoparticles  and  to  study the  burst  release  pattern  with  chitosan  nanoparticle
alone and chitosan with sodium alginate and sodium chloride. The formulations
were made by mixing (1:1, 1:2. 1:3) different ratios of drug and polymer in both
plain chitosan nanoparticles and with sodium alginate chitosan nanoparticles.
The concentration of sodium alginate was kept 0.1 %, 0.2% and 0.3% w/v
in three formulations of sodium alginate chitosan nanoparticles.
Preparation of plain chitosan nanoparticles 
Chitosan nanoparticles were synthesized via the ionic gelation of chitosan
with  TPP anions.  Chitosan was dissolved in  acetic  aqueous solution at  various
concentrations. The concentration of acetic acid in aqueous solution was 1.5 time
higher than that of chitosan. The pH of chitosan solution was adjusted to 5.5 by 2
N  NaOH  solution  after  adding  specified  quantity  of  valsartan  into  chitosan
solution.  The  TPP solution  (1  mg/mL) was prepared by double-distilled water.
Chitosan nanoparticles were spontaneously fabricated with the dropwise addition
of 5 mL of the chitosan solution to 2 mL of TPP solution under magnetic stirring
(1000 rpm, 1 hour) at room temperature. The opalescent suspension was formed
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under the same above mentioned conditions. The nanoparticles were separated by
centrifugation at 10,000 rpm and 14°C for 30 minutes, freeze-dried and stored at 5
±  3°C.  The  weights  of  freeze-dried  nanoparticles  were  also  measured.  The
formulation of chitosan nanoparticles is shown in Table.1.
Preparation of alginate-chitosan nanoparticles
The chitosan nanoparticles were prepared by the same procedure,  except
that various amounts of sodium alginate were dissolved in the TPP solution before
adding the chitosan-valsartan solution. Chitosan nanoparticles were formed upon
adding  the  TPP solution  to  chitosan-  valsartan  solution  and  mixing.  After  ten
minutes of mixing these two solutions, 0.9 g calcium chloride was added to the
suspension which was stirred for 20 min. Finally, the nanoparticles were isolated
by centrifugation at 6000 rpm for 40 min. The formulation of alginate-chitosan
nanoparticles is shown in Table. 2. 7,16,19
EVALUATION  OF  THE  VALSARTAN  CONTAINING  CHITOSAN
NANOPARTICLES 
Drug-polymer compatibility study
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Drug-polymer compatibility study was carried out by FTIR (ATR). Spectra
were recorded for pure drug, polymer and for drug and polymer physical mixture.
The FTI-IR spectrum pure drug sample and pure polymer sample with formulation
were  recorded  to  find  out  whether  any  interaction  of  drug  with  polymer  was
present in formulations. 18,62
Practical yield
Freeze  dried  nanoparticles  were  collected  and  weighed  to  determine
practical yield (PY) from the following equation, 17,63,64
PY (%) =                                     Nanoparticles weight                              × 100% 
Theoretical mass of drug + polymer +
TPP
The individual values for three replicates were determined, and their mean
values are reported. 
Characterization of nanoparticles for particle size analysis
The particle size of the Nanoparticles was evaluated by Scanning Electron
Microscope (SEM) to find out the size of the nanoparticles and to study the surface
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morphology of the nanoparticles. Dried particles were taken in a piece of black
tape and attached to the sample holder. Particle morphology was determined under
low vacuum. The SEM method provides a finest approach to find out particles size
and surface morphology when compared to other methods. 20,65
Measurement of mean particle size
The mean  size  of  the  nanoparticles  was  determined  by photocorrelation
spectroscopy (PCS) on a submicron particle size analyzer (Malvern Instruments) at
a scattering angle of 90°. A sample of 0.5mg of the nanoparticles suspended in 5
ml of distilled water was used for the measurement. 21 23, 66, 67
Determination of percentage of drug entrapment efficiency 
The  Nanoparticle  suspension  was  centrifuged  at  12000  rpm  in  cooling
centrifuge  at  15oC  for  10  min.  The  supernatant  fluid  was  analysed
spectrophotometrically.
                                         Amount of Drug in the Nanoparticles
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Drug Entrapment (%) = ------------------------------------------------- × 100
                                          Amount of Drug fed in to system
The above method can be useful to find out the percentage of drug entrapped into
the nanoparticles. 20,68
Determination of zeta potential
The zeta potential of the drug-loaded chitosan nanoparticles was measured
on a zetasizer (Malvern Instruments) by determining the electrophoretic mobility
in a micro electrophoresis flow cell. Zeta potential is highly useful for physical
stability of colloidal dispersions and it can be measured by determination of the
movement  velocity of  the particles in  an electric field.  It  limits  ranged from –
200mV to + 200mV. All the samples were measured in water at 25 °C in triplicate
and the samples were diluted 10 times before measurement of zeta potential. The
zeta potential was measured by Malvern zetasizer UK. 21 26,69
Evaluation of in vitro drug release
The chitosan nanoparticles, after separation by ultracentrifugation, were re-
dispersed in  5ml  buffer  solution  PBS solution  of  pH 6.8,  placed in  a  dialysis
membrane bag, tied and immersed in 150ml buffer in 250ml beaker. The entire
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system was  stirred  continuously  at  37 °C by using a  magnetic  stirrer.  At  pre-
determined time intervals, 5ml of the release medium was removed and replaced
with 5ml of fresh buffer solution. The amount of drug in the release medium was
evaluated by UV spectrophotometry at 250nm. 25, 70
Stability studies
Valsartan nanoparticles were stored at 2-8°C in refrigerator and 30º C ± 2º
C/65% ± 5% RH in humidity chamber for 60 days to find out the stability of the
formulations. The optimized formulation stored in the sealed aluminium foil. The
optimized  formulation  was  analyzed  after  30  and  60  days  for  appearance,
percentage drug entrapment efficiency and in vitro drug release. 20, 71
RESULTS AND DISCUSSION
CALIBRATION CURVE OF VALSARTAN
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            Calibration curve of valsartan was done in phosphate buffer pH-6.8.
Valsartan  shows  λmax of  250  nm in  phosphate  buffer  pH-6.8.  The  correlation
coefficient  was  0.999.  Hence,  Valsartan  obeys  the  beer’s  law  within  the
concentration  range  of  10  to  50µg/ml.  The  calibration  plot  of  valsartan  in
phosphate buffer pH-6.8 was showed in fig.5. 
FORMULATION OF  VALSARTAN  CONTAINING  PLAIN  CHITOSAN
NANOPARTICLES AND ALGINATE CHITOSAN NANOPARTICLES BY
IONIC GELATION METHOD
            Six formulations of valsartan as plain and alginate chitosan nanoparticles
were  prepared  by  using  various  concentrations  of  (1:1,  1:2,  1:3)  chitosan  and
valsartan  were  formulated  by  using  ionic  gelation  technique.  The  drug
concentration kept as constant for each formulation (40mg).
                           
            The two main reasons for selection of the method was to compare the
release pattern of plain chitosan nanoparticles with alginate nanoparticles to show
the burst release of drug in plain chitosan and less burst release in alginate chitosan
nanoparticles.        
 EVALUATION OF FORMULATION
Drug-polymer compatibility study
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FT-IR spectra of pure drug valsartan, chitosan and combination of drug and
polymer were obtained. The figures are shown in Fig 6, Fig 7 and in Fig 8.  FTIR
Spectra  showed  peaks  around  1655,  1534  and  3309  cm-1,  reflecting  the
acetylamino I, acetylamino II and (NH2) groups, respectively. The characteristic
peaks of sodium alginate included O-H at 3397 cm-1, COO- (asymmetric) at 1617,
COO- (symmetric) at 1429 and 1028 cm-1 for C-O-C stretching.  The spectrum
was indication of intramolecular and intermolecular hydrogen bonds which were
formed and enhanced between chitosan and alginate molecules. From the obtained
spectra it was observed that all the characteristics peaks of valsartan were present
in the combination spectra thus indicating the compatibility of the drug with the
polymer  used.  It  shows  that  there  was  no  significant  change  in  the  chemical
integrity of the drug.
Practical yield
The practical yields of the formulations were calculated and it was nearly
90 – 95 % for all the formulations.
Characterization of nanoparticles for particle size analysis
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The particle size analysis of the nanoparticles reveals that the particle sizes
were ranges from 100 – 200 nm and the particles were in nanometer size range.
The SEM photography of the formulations was shown in Figure.9.
Measurement of mean particle size and PDI
The mean particle size and PDI was found in range of 105 – 198 nm and
0.075  -  0.129  respectively  for  the  plain  chitosan  nanoparticles  and  the  mean
particle  size  and  PDI  was  found  to  be  115  –  220  nm  and  0.251  –  0.392
respectively.  The  both  the  plain  chitosan  nanoparticles  and  alginate  chitosan
nanoparticles were found be within nanometer size range. The Values were shown
in Table.3 and in figure 10 and 11.
Determination of percentage of drug entrapment efficiency
The drug entrapment efficiency was ranges from 74.26 % - 78.56 % for the
plain chitosan nanoparticles and it shows the increase in concentration of chitosan
leads  to  increase  in  entrapment  efficiency.  The  drug  entrapment  efficiency  of
alginate chitosan nanoparticles ranges from 80.23 – 85.12 % and the concentration
of chitosan and alginate both increases the drug entrapment efficiency when the
concentration increases. The Values were shown in Table.3 and in Figure 12.
Determination of zeta potential
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Zeta potential of the plain chitosan nanoparticles was found in the range of
 -12.05±46 to -16.04±04 mV and the chitosan alginate nanoparticles range from
-12.23±05  to  -15.06±57  mV.  The  results  of  Zeta  potential  revealed  that  all
formulations were found stable. The Values were shown in Table.3.
Evaluation of In vitro drug release
The In-vitro drug release studies were carried out by using dialysis bag. The
data  of  cumulative  percentage drug  release  of  the  formulations  were  shown in
Table.4, and in Figure 13. The cumulative percentage drug release after 60 h was
studied.
The percentage drug release  of  plain  chitosan nanoparticles  ranges  from
91.45 –  99.13% at  the  end of  60 hrs.  The percentage drug release  of  alginate
chitosan  nanoparticles  ranges  from 60.12  –  85  23  % at  the  end  of  60  hrs.  In
alginate  chitosan  nanoparticles  the  interaction  between  chitosan  matrix  and
alginate and ionotropic gelation of sodium alginate with CaCl2 in alginate chitosan
nanoparticles may also contribute to enhanced cross-linking density of the matrix.
Increased cross-linking density may lead to lower diffusion of the drug from the
matrix  leads  to  decreased  burst  release  and  rate  of  release.  Among  all  the
formulation  the  F6 which contains  high concentration  of  alginate  and  chitosan
shows less burst release and sustained release of 60.12% which was chosen as
optimized formulation.
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Stability studies
Stability studies were carried out to find out the stability and changes in
appearance  and  entrapment  efficiency  for  optimized  formulation  F6.  The
formulation was stored at 30±2°C/65±5% RH for two months. The results were
shown Table 5 and figure 14. The results showed that  there was no significant
difference in appearance and entrapment efficiency. 
BIBLIOGRAPHY
81
1. Nishikant  C Shinde,  Nisha J  Keskar,  Prashant  D Argade “Nanoparticles:
Advances in Drug Delivery Systems”. Research Journal of Pharmaceutical,
Biological and Chemical Sciences, 2012; 3 (1): 922.
2. Nagavarma B V N, Hemant K.S. Yadav, Ayaz a, Vasudha L.S, Shivakumar
H.G. “Different  techniques for  preparation of  polymeric  nanoparticles-  a
review”.  Asian  Journal  of  Pharmaceutical  and  Clinical  Research,  2012;
5(3).
3. Waree  Tiyaboonchai.  “Chitosan  Nanoparticles:  A Promising  System  for
Drug Delivery”. Naresuan University Journal, 2003; 11(3): 51-66.
4. Ashish  Kumar  Kosta,  Mohit  Solakhia  T,  Shikha  Agrawal.  “Chitosan
Nanoparticle  -  A  Drug  Delivery  System”.  International  Journal  of
Pharmaceutical & Biological Archives, 2012; 3(4):737-743.
5. Stefania  Racovita,  Silvia  Vasiliu,  Marcel  Popa,  Cornelia  Luca.
“Polysaccharides  based  on  micro-  and  nanoparticles  obtained  by  ionic
gelation and their applications as drug delivery systems”. Revue Roumaine
de Chimie, 2009, 54(9), 709–718.
6. Ylenia Zambito. “Nanoparticles Based on Chitosan Derivatives”. Advances
in Biomaterials Science and Biomedical Applications.
7. Morteza  Hasanzadeh  Kafshgari,  Mohammad  Khorram,  Mobina
Khodadoost,and Sahar Khavari. “Reinforcement of Chitosan Nanoparticles
Obtained  by  an  Ionic  Cross-linking  Process”.  Iranian  Polymer  Journal,
2011; 20 (5): 445-456.
82
8. Jun Jie Wang, Zhao Wu Zeng, Ren Zhong Xiao, Tian Xie, Guang Lin Zhou,
Xiao Ri Zhan, Shu Ling Wang. “Recent advances of chitosan nanoparticles
as drug carriers”. International Journal of Nanomedicine 2011; 6: 765–774.
9. Chen F, Zhang Z-R, Huang Y. “Evaluation and modification of N-trimethyl
chitosan chloride nanoparticles as protein carriers”. Int J Pharm, 2007; 336:
166-173.
10. Sheikh  Hassan  A,  Sapin  A,  Lamprecht  A,  Emond  E,  El  Ghazouani  F,
Maincent P. “Composite microparticles with in vivo reduction of the burst
release effect:. Eur J Pharm Biopharm, 2009; 73: 337- 344.
11. Tavakol  M,  Vasheghani-Farahani  E,  Dolatabadi-  Farahani  T,  Hashemi-
Najafabadi  S.  “Sulfasalazine  release  from  alginate-N,O-carboxymethyl
chitosan gel beads coated by chitosan”.  Carbohyd Polym, 2009;  77: 326-
330.
12. Sarmento  B,  Ribeiro  A,  Veiga  F,  Sampaio  P,  Neufeld  R,  Ferreira  D.
“Alginate/chitosan  nanoparticles  are  effective  for  oral  insulin  delivery”.
Pharm Res, 2007; 24(12):2198–206.
13. Anumita Chaudhury, Surajit Das. “Recent Advancement of Chitosan-Based
Nanoparticles  for  Oral  Controlled  Delivery  of  Insulin  and  Other
Therapeutic Agents”. AAPS PharmSciTech, 2011; 12 (1): 10 – 20.
14. Hoang  Hai  Nguyena,  Sae-Yeol-Rim  Paika,  Seung-Chul  Yanga,  Pei  Sia
Leea,  Pradeep Puligundlaa,  Sanghoon Koa.  “Preparation of  size-tailored,
similar surface characteristic chitosan nanoparticles by ionotropic gelation”.
83
15. Calvo  et  al.,  “Novel  Hydrophilic  Chitosan-Polyethylene  Oxide
Nanoparticles  as  Protein  Carriers”.  Journal  of  Applied Polymer  Science,
1997; 63, 125-132. 
16. Mohammadpour Dounighi N, Eskandari R, Avadi MR, Zolfagharian H, Mir
Mohammad  Sadeghi  A,  Rezayat  M.  “Preparation  and  in  vitro
characterization  of  chitosan  nanoparticles  containing  Mesobuthus  eupeus
scorpion venom as an antigen delivery system”. The Journal of Venomous
Animals and Toxins including Tropical Diseases, 2012; 18 (1): 44-52.
17. J.  Adlin  Jino  Nesalina.  A.  Anton  Smith.  “Preparation and  evaluation  of
chitosan  nanoparticles  containing  zidovudine”.  Asian  Journal  of
Pharmaceutical Sciences, 2012; 7 (1): 80-84.
18. Qian-ying  deng,  Chang-ren  zhou  and  Bing-hong  Luo.  “Preparation  and
characterization  of  chitosan  nanoparticles  containing  lysozyme”.
Pharmaceutical Biology, 2006; 44(5): 336-342.
19. Stoica.  R.,  Şomoghi.R,  Ion.R.M.,  “Preparation  of  chitosan  –
tripolyphosphate  nanoparticles  for  the  encapsulation  of  polyphenols
extracted  from  rose  HIPS”.  Digest  Journal  of  Nanomaterials  and
Biostructures, 2013; 8(3): 955 – 963.
20. Umasankar.  K.,  and  Uma  Maheswara  Reddy.C.  “Formulation  and
Evaluation  of  Cytarabine  Nanoparticles”.  International  Journal  of
Innovative Pharmaceutical Researc, 2010; 1(2): 48-52.
84
21. Amar Singh and Amar Deep. “Formulation and Evaluation of Nanoparticles
containing  Losartan  Potassium”.  International  Journal  of  Pharmacy
Research and Technology, 2011; 1(1): 17-20.
22. Partha Saha, Amit K Goyal and Goutam Rath. “Formulation and Evaluation
of Chitosan- based Ampicillin Trihydrate Nanoparticles”.  Tropical Journal
of Pharmaceutical Research, 2010; 9 (5): 483-488.
23. Amir  Dustgania,  Ebrahim  Vasheghani  Farahania,  Mohammad  Imanib.
“Preparation of Chitosan Nanoparticles Loaded by Dexamethasone Sodium
Phosphate”. Iranian Journal of Pharmaceutical Sciences Spring, 2008; 4(2):
111-114.
24. Hong-liang Zhang, Si-huiWu,Yi Tao, Lin-quan Zang, and Zheng-quan Su.
“Preparation and Characterization of Water-Soluble Chitosan Nanoparticles
as Protein Delivery System”. Journal of Nanomaterials, 2010; 5.
25. Prajapati  Maheshkumar  D,  Shantha  Kumar.G.S.,  Divakar  Goli,  Roopa
Karki.  “Design,  development  and  evaluation  of  nanoparticles  of  poorly
soluble  valsartan”.  World  Journal  of  Pharmacy  and  Pharmaceutical
Sciences,2013; 2(6): 5737-5749.
26. Parmar. B., Mandal. S, Petkar. K.C., Patel. L.D., Sawant. K.K. “Valsartan
loaded solid lipid nanoparticles: Development, chatarcterization and in vitro
and ex vivo evaluation”.  International Journal of  Pharmaceutical  Science
and Nanotechnology, 2011; 4 (3):1483 - 1490.
27. Kashinatha B.P. Shivakumar S., Devprakash, Prashant Singh. “Design and
evaluation of transdermal film of valsartan by using modified polymer”.
Journal of Pharmacy Research 2012; 5(5): 2823-2829.
85
28. Hiral  Patel,  Vijay  Oza,  Akshay  Koli,  Ketan  Ranch  and  Dinesh  Shah.
“Formulation Development and Evaluation of Lipid Based Nanoparticles of
Valsartan by Microemulsification”.  Drug Delivery Letters,  2013;  3:  200-
209.
29. Dan Peer, Jeffrey M. Karp, Seungpyo Hong, Omid C., Farokhzad, Rimona
Margalit  and  Robert  Langer.  “Nanocarriers  as  an  emerging  platform for
cancer therapy”. Nature Nanotechnology, 2007; 2: 751 – 760.
30. Catarina  Pinto  Reis,  Ronald  J.  Neufeld,  Anto  nio  J.  Ribeiro,  Francisco
Veiga,  “Nanoencapsulation  I.  Methods  for  preparation  of  drug-loaded
polymeric  nanoparticles,  Nanomedicine:  Nanotechnology”.  Biology,  and
Medicine, 2006; 2: 8 – 21.
31. Lucretiu  Cismaru  and  Marcel  Popa,  “Polymeric  nanoparticles  with
biomedical applications”. Rev. Roum. Chim, 2010; 55(8): 433-442.
32. Ajay  Verma,  Sanjay  Ratnawat,  Arun  K.  Gupta,  Sanjay  Jain.  “PLGA
Nanoparticles for Delivery of Losartan Potassium through Intranasal Route:
Development  and  Characterization”.  International  Journal  of  Drug
Development & Research, 2013; 5(1): 185 – 196.
33. Meetali  Mudgil,  Nidhi  Gupta,  Manju  Nagpal,  Pravin  Pawar.
“Nanotechnology:  A  new  approach  for  ocular  drug  delivery  system”.
International  Journal  of  Pharmacy and Pharmaceutical  Sciences,  2012;  4
(2): 105 – 112.
34. Agnihotri. “Recent advances on chitosan-based micro- and nanoparticles in
drug delivery”. Journal of Controlled Release, 2004; 100: 5-28.
86
35. Atkas.  “Preparation  and  in  vitro  evaluation  of  chitosan  nanoparticles
containing  a  caspase  inhibitor”.  International  Journal  of  Pharmaceutics,
2005; 298: 378-383.
36. Gan.  “Modulation  of  surface  charge,  particle  size  and  morphological
properties  of  chitosan-TPP  nanoparticles  intended  for  gene  delivery”.
Colloids and Surfaces B: Biointerfaces, 2005; 44: 65-73.
37. Janes.  “Polysaccharide  colloidal  particles  as  delivery  systems  for
macromolecules”. Advanced Drug Delivery Reviews, 2001; 47: 83-97.
38. Lavertu. “High efficiency gene transfer using chitosan/DNA nanoparticles
with  specific  combinations  of  molecular  weight  and  degree  of
deacetylation”. Biomaterials, 2006; 27, 4815-4824. 
39. Vila.  “Low molecular  weight  chitosan  nanoparticles  as  new carriers  for
nasal vaccine delivery in mice”. European Journal of Pharmaceuticals and
Biopharmaceuticals, 2003; 57: 123-131.
40. Li  T,  Shi  XW,  Du  YM,  Tang  YF.  “Quaternized  chitosan/alginate
nanoparticles  for  protein  delivery”.  J  Biomed  Mater  Res  A.  2007;
83(2):383–90.
41. Diovan. [Electronic version]. e-CPS. Retrieved September 15, 2011.
42. http://reference.medscape.com/drug/diovan-valsartan-342325#10
43. http://en.wikipedia.org/wiki/Valsartan 
44. http://www.medicinenet.com/valsartan/article.htm 
45. http://www.rxlist.com/diovan-drug.htm
46. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697015.html
87
47. http://www.drugbank.ca/drugs/DB00177.
48. Bader, M. “Renin-angiotensin-aldosterone system”. In S. Offermanns, & W.
Rosenthal  (Eds.). Encyclopedic  reference  of  molecular  pharmacology.
2004; 810-814.
49. Stanfield,  C.L.,  &  Germann,  W.J. “Principles  of  human
physiology (3 rd ed.)”. San Francisco, CA: Pearson Education, Inc.2008.
50.  Sweetman SC, ed. Martindale: “The Complete Drug Reference”, 36th edn.
London: Pharmaceutical Press, 2009; 2244–2245.
51. Fenner  PJ,  Williamson JA.  “Worldwide deaths  and severe envenomation
from jellyfish stings”. Med J Aust 1996; 165: 658–661.
52. Milner  SM. “Acetic  acid  to  treat  Pseudomonas  aeruginosa in  superficial
wounds and burns”. Lancet 1992; 340: 61.
53. Lewis  RJ,  ed.  “Sax’s  Dangerous Properties  of  Industrial  Materials”,  11th
edn. New York: Wiley, 2004; 670.
54. Donnelly  WR.  “Exothermic  composition  and  hot  pack”.  United  States
Patent 4203418; 1980.
88
55. Wei X et al. “Sigmoidal release of indomethacin from pectin matrix tablets:
effect of in situ crosslinking by calcium cations”. Int J Pharm 2006; 318:
132–138.
56. Rege  PR  et  al.  “Chitinosan-drug  complexes:  effect  of  electrolyte  on
naproxen release in vitro”. Int J Pharm 2003; 250: 259–272.
57. Luessen HL et al. ‘Mucoadhesive polymers in peroral peptide drug delivery,
IV:  polycarbophil  and chitosan are potent  enhancers  of  peptide transport
across intestinal mucosae in vitro”. J Control Release 1997; 45: 15–23.
58. Tozaki H et al.  ‘Validation of a pharmacokinetic model of colon-specific
drug delivery and the therapeutic effects of chitosan capsules containing 5-
aminosalicylic  acid  on  2,4,6-  trinitrobenzene  sulphonic  acid-induced
ulcerative colitis in rats”. J Pharm Pharmacol 1999; 51: 1107–1112.
59. Tozaki H et al. “Colon specific delivery of R 68070, a new thromboxane
synthase inhibitor using chitosan capsules: therapeutic effects against 2,4,6-
trinitrobenzene sulphonic acid-induced ulcerative colitis in rats”. Life Sci
1999; 64: 1155–1162.
60.  Raymond C Rowe, Paul J Sherkey, Sian C. “Hand book of Pharmaceutical
Excipients”, Fifth Ed.5-6,  89 – 90, 159 – 160, 622 – 624. 
61.  Leong KW et al. “DNA-polycation nanospheres as non-viral gene delivery
vehicles”. J Control Release 1998; 53: 183–193.
62. Lin YH, Mi FL, Chen CT, Chang WC, Peng SF, Liang HF. “Preparation and
characterization  of  nanoparticles  shelled  with  chitosan  for  oral  insulin
delivery”. Biomacromolecules. 2007; 8 (1):146–52.
89
63. Sarmento B, Ferreira DC, Jorgensen L, van de Weert M. “Probing insulin’s
secondary structure after entrapment into alginate/chitosan nanoparticles”.
Eur J Pharm Biopharm. 2007; 65 (1):10–7.
64. Zhang N,  Li  J,  Jiang  W,  Ren  C,  Li  J,  Xin  J.  “Effective  protection  and
controlled release  of  insulin  by cationic  betacyclodextrin  polymers  from
alginate/chitosan nanoparticles”. Int J Pharm. 2010; 393(1–2):212–8.
65. Li J, Xiao H, Li J, Zhong Y. “Drug carrier systems based on water-soluble
cationic beta-cyclodextrin polymers”. Int J Pharm. 2004; 278(2):329–42.
66. Huang L, Xin J, Guo Y, Li J. “A novel insulin oral delivery system assisted
by cationic B-cyclodextrin polymers”. J Appl Polym Sci, 2010; 115:1371–
9.
67. Joseph NM, Sharma PK and Irchhaiya R. “Preparation and characterization
of  Modified  Gelation  Nanoparticles  as  Carriers  of  Cytarabine”.  Asian
Journel of Pharmaceutis. 2007; 1: 179.
68. Kim  YH,  Hwang  HY,  Kim  I  and  Kwon  IC.  “Tumor  targetability  and
antitumor  effect  of  docetaxel  loaded  hydrophobically  modified  glycol
chitosan nanoparticles”. J. Control. Rel. 2008; 74: 317-323.
69. Krishna RSM, HG Shivakumar,  DV Gowda, Banerjee.  “Nanoparticles: A
Novel Colloidal Drug Delivery System”.  Indian J.Pharm.Educ.Res. 2006;
40(1):15-19.
70. Lifeng Qi and Xu Z, Invivo. “Antitumar activity of chitosan nanoparticles”.
Bioorganic and Med. Chemistry Letters. 2006; 16: 4243- 4245.
90
71. Poirier A, Cascais AC, Funk C, Lave T.  “Prediction of pharmacokinetic
profile of  valsartan in human based on in vitro uptake transport  data”.  J
Pharmacokinet Pharmacodyn. 2009 Dec; 36(6): 585-611. 
91
